Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X RED Bevacizumab (CoagadexAvastin®) ICB Radiation retinopathy macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Bexarotene (Targretin®) NHSE Hereditary factor X deficiency All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Bezafibrate (Bezalip; Fibrazate) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" Not recommended for routine use CG181 - Jul 14 BLACK Bezlotoxumab (Zinplava®) ICB Prevention of recurrent clostridium difficile infection (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA601 - Sep 19 RED Bictecravir (in combination with emtricitabine and tenofivir alafenamide) Biktarvy ®) NHSE HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Bimagrumab ((BYM338)) NHSE Inclusion body myositis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII RED Bimekizumab Bimzelx® ICB active psoriatic arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA916 – October 2023 RED Bimekizumab Bimzelx® ICB axial spondyloarthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA918 – October 2023 RED Bimekizumab Bimzelx® ICB moderate to severe plaque psoriasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA723 – September 2021 RED Binimetinib (Mektovi®) NHSE Specialist indications (with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults - as per NICE TA 562 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA562 - Feb 19 BLACK Bioidentical HRT (Bioidentical hormone replacement therapy) ICB Menopausal symptoms Not commissioned. No NHS prescribing in primary or secondary care NG23 - Nov 13 RED Biotin (vitamin H) (Qizenday®, Cerenday®, MD1003) NHSE various Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor RED Birch bark extract n/a NHSE epidermolysis bullosa Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST28 – September 2023 RED Bivalirudin (FEIBAAngiox®) ICB Treatment of ST-segment-elevation myocardial infarction - as per NICE TA 230 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA230 - Jul 11 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Blinatumomab (Blincyto®) NHSE Specialist indications Acute lymphoblastic leukaemia in remission with minimal residual disease activity Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA589 - Jul 19 BLACK Blinatumomab N/A NHSE previously treated Philadelphia- chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA686 – March 2021 RED Blinatumomab ▼ (Blincyto® ▼) NHSE Philadelphia-chromosome-negative relapsed or refractory precursor B- cell acute lymphoblastic leukaemia in adults - as per NICE TA 450 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA450 - Jun 17 RED Blisibimod () NHSE Systemic lupus erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine RED Boceprevir (FampyraVictrelis®) NHSE Improvement Treatment of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) genotype 1 chronic hepatitis C - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema TA 253 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration TA253 - Apr 12 RED Bortezomib (Velcade®) NHSE Multiple myeloma (first line) - as per NICE 228 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat TA228 - Jul 11 RED Bortezomib (AdenuricVelcade®) ICB Management of chronic hyperuricaemia NHSE Induction therapy in patients with gout who are intolerant of allopurinol multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis 311 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® TA311 - Apr 14 RED Bortezomib (Velcade®) NHSE seizures associated with Dravet syndrome Previously untreated mantle cell lymphoma in adults for whom haematopoietic stem cell transplantation is unsuitable as per NICE TA 370 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD TA370 - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12Dec 15
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Botulinum Toxin Type A (Dysport®) ICB Muscle spasticity in neuromuscular conditions - cerebral palsy - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Botulinum Toxin Type A (FEIBABotox®, Dysport®) ICB Treatment of focal spasticity in Multiple Sclerosis or following stroke or brain injury - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Botulinum Toxin Type A and B (Botox®) NHSE Specialist indications Intravesical use in spinal cord injury Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Botulinum Toxin Type A and B (Botox®) NHSE Focal spasticity in children Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Brentuximab vedotin (Adcetris®) NHSE CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease - as per NICE TA 524 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA524 - Jun 18 Hospital Brentuximab vedotin (Adcetris®) NHSE Treating CD30-positive cutaneous T- cell lymphoma (CTCL) after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome - as per NICE TA 577 (NHSE comm Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA577 - Apr 19 BLACK Brentuximab vedotin (Adcetris®) NHSE Untreated advanced Hodgkin lymphoma (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA594 - Aug 19 Hospital Brentuximab vedotin (Adcetris®) NHSE in combination for untreated systemic anaplastic large cell lymphoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA641 – August 2020 Hospital Brentuximab vedotin ▼ (Adcetris® ▼) NHSE CD30-positive Hodgkin lymphoma - as per NICE TA 446 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA446 - Jun 17 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Brentuximab vedotin ▼ (Adcetris® ▼) NHSE For treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - as per NICE TA 478 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA478 - Oct 17 Hospital Brexucabtagene autoleucel Tecartus® NHSE relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA893 – June 2023 Hospital Brigatinib (Alunbrig®) NHSE For treating ALK-positive advanced non-small-cell lung cancer in adults, after crizotinib - as per NICE TA 571 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA571 - Mar 19 Hospital Brigatinib Alunbrig® NHSE ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA670 – January 2021 Hospital Brimapitide NHSE Acute sensorineural hearing loss Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine Brimonidine tartrate gel (FampyraMirvaso®) NHSE Improvement ICB Treatment of walking in adults with Multiple Sclerosis with walking disability facial erythema (EDSS 4-7rosacea) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat Brincidofovir (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indicationCMX001). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications CMV infection Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) Brivaracetam Briviact ICB Treatment of mild epilepsy as alternative to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy levetiracetam Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication Hospital Brodalumab (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib JyselecaKyntheum®) ICB Moderate to severe rheumatoid arthritis plaque psoriasis - as per NICE TA 511 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 TA511 - Mar 18 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Brolucizumab Beovu® ICB Wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib JyselecaTA672 – February 2021 BLUE Brolucizumab Beovu® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes diabetic macular oedema NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ TA820 – August 2022 BLACK Bromocriptine (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis ICB Pharmacological neuroprotective therapy in Xxxxxxxxx'x disease (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 BLACK Bromocriptine mesilate (Parlodel®) ICB First-line use in Xxxxxxxxx'x disease - as per NICE TA 254 NG 17 Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 ADVICE Budenofalk (Budenofalk®) ICB Crohn's disease in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. ADVICE Budenofalk (Budesonide 3mg caps & 9mg granules) (Budenofalk®) ICB Collagenous colitis in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. BLACK Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults - treatment for maintenance of remission Not commissioned. No NHS prescribing in primary or secondary care TA708 – June 2021 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (GP may issue a SINGLE follow-up treatment (NOT for repeat) only if deemed necessary following assessment of response to initial treatment by given the hospital) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. TA708 – June 2021 Hospital Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (first treatment with follow-up assessment of effectiveness by the hospital) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 TA708 – June 2021 Hospital Bulevirtide Hepcludex® NHSE chronic hepatitis D Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA896 – June 2023 GREEN Buprenorphine (sublingual & oral lyophilisate) (Subutex® - Apr 12generics available / Espranor®) NCC Opioid dependence (for use by prescribers with competence in treating opioid dependence) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. ADVICE Buprenorphine (transdermal) (Butec®, Transtec® patches) ICB Patients with renal impairment (eGFR 15-30, CKD 4) who have an accumulation of opiates and a resulting potential for toxicity Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. BLUE Buprenorphine Long- Acting Injection Buvidal®) ICB opioid substitution treatment NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required RMOC - April 2021 GREEN Bupropion (Zyban®) NCC Adjunct to smoking cessation Formulary - Drugs that can be initiated by Prescriber in Primary Care NG92 - Mar 18 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Burosumab (Crysvita®) NHSE X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in young people with growing bones - as per NICE HST 8 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST8 - Oct 18 Double Red Buspirone (Generics are available) ICB Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do Not recommended for routine use CG90 - Oct 09 Hospital Busulfan (Myleran®) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Butyrophenones (benperidol and haloperidol) (Various) ICB NICE Do Not Do - Use in Xxxxxxxxx'x disease - as per NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Hospital C1 Esterase Inhibitors NHSE Hereditary angioedema treatment and prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Cabazitaxel (Jevtana®) NHSE Hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen - as per NICE TA 255 Not commissioned. No NHS prescribing in primary or secondary care TA255 - May 12 Hospital Cabazitaxel (Jevtana®) NHSE Metastatic hormone relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy - as per NICE TA 391 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA391 - Aug 16 BLACK Cabergoline (Cabaser®) ICB First-line use in Xxxxxxxxx'x disease - as per NICE NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Hospital Cabotegravir Vocabria® NHSE HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Cabotegravir Vocabria® NHSE with rilpivirine for treating HIV-1 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA757 – January 2022 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Cabozantinib (Cometriq®) NHSE For treating medullary thyroid cancer - as per NICE TA 516 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA516 - Mar 18 Hospital Cabozantinib (Cabometyx®) NHSE Untreated advanced renal cell carcinoma in adults under defined circumstances - as per NICE TA 542 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA542 - Oct 18 Hospital Cabozantinib Cabometyx® NHSE previously treated advanced hepatocellular carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA849 – December 2022 BLACK Cabozantinib Cabometyx® NHSE previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine Not commissioned. No NHS prescribing in primary or secondary care TA928 – November 2023 Hospital Cabozantinib ▼ (Cabometyx® ▼) NHSE Previously treated advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)- targeted therapy - as per NICE TA 463 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA463 - Aug 17 Hospital Calcifidiol NHSE Inborn errors in primary bile acid synthesis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Calcium and Ergocalciferol combi tablets (Generic tablets) ICB Prevention of osteoporosis-related fractures and falls Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Double Red Calcium channel blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 - NICE Do Not Do Not recommended for routine use CG101 - Jul 10 ADVICE Canagliflozin ▼ (Invokana® ▼) ICB In combination therapy for treating type 2 diabetes - as per NICE TA 315 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA315 - Jun 14
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Double Red Clomethiazole (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraHeminevrin®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4PHE Community-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol based assisted alcohol withdrawal - as per NICE TA 164 CG 115 - Do Not Do Not recommended for routine use CG115 - Feb 11 GREEN Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Prevention of atherosclerotic events Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 TA210 - Dec 08 10 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted Clopidogrel (Plavix®, generics approved for use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®- Sept 2009) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl IProphylaxis pre-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care elective PCI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol Clopidogrel (FeraccruPlavix®) (Feraccru®, generics approved for use - Sept 2009) ICB Treatment Primary prevention of iron-deficiency anaemia CVD in adults (see separate Red entry regarding use in IBD) T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol NG17 - May 17 Double Red Clopidogrel (FeraccruPlavix®) (Feraccru®, generics approved for use - Sept 2009) ICB Treatment Primary prevention of iron-deficiency anaemia CVD in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital T1 or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia T2 Diabetes - as per BCSH guidelines Restricted NG17 and NG 28 Do Not Do's Not recommended for routine use – Prescribing to remain NG28 - May 17 ADVICE Clopidogrel (with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 low dose aspirin) (FGF1) gene therapy () NHSE All indications Restricted Plavix®, generics approved for use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®- Sept 2009) ICB Treatment of mild to moderate C. difficile infection Acute Coronary Syndrome without ST- segment elevation (CDINSTEMI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy (with aspirin) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script. TA80 - Jul 04 ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB Post elective percutaneous coronary intervention (PCI) - bare metal stent (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in-patient stay. NICE has not issued any guidance. ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB ST-elevation myocardial infarction (STEMI) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in patient stay; max one month. NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib JyselecaClozapine (Clozaril®, Denzapine®, Zaponex®) ICB Moderate to severe rheumatoid arthritis Schizophrenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 CG82 - Mar 09 Hospital Filgotinib Cobicistat ▼ () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib JyselecaTybost® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction Use as a booster in the duration treatment of neutropenia HIV positive adults and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy adolescents - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod BLACK Cobimetinib ▼ (Gilenyain combination with vemurafenib) (Cotellic® ▼) NHSE Highly active relapsing remitting multiple sclerosis Unresectable or metastatic BRAF V600 mutation-positive melanoma - as per NICE TA 254 414 Not commissioned. No NHS prescribing in primary or secondary care TA414 - Oct 16 Hospital Co-careldopa intestinal gel (Duodopa® ▼) NHSE Severe Xxxxxxxxx'x disease inadequately controlled by other preparations - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 NICE has not issued any guidance. Hospital Cochlear implants (Various) NHSE For children and adults with severe to profound deafness - Apr 12specialist commissioned use only as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA566 - Mar 19 Double Red Codeine linctus generic ICB Cough suppressant Not recommended for routine use NICE has not issued any guidance BLACK Co-enzyme Q10 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 17 BLACK Co-enzyme Q11 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 GREEN Colecalciferol (Vitamin D) (Licensed Vitamin D products) ICB Treatment of vitamin D deficiency in adults and children - as per local policies Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. BLACK Colecalciferol (Vitamin D) (Various) ICB To increase adherence to statin treatment - as per NICE CG 181 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Colesevelam HCl (Cholestagel®) ICB Third-line option for (unlicensed) use in bile salt malabsorption causing diarrhoea (for patients under the NNUH only) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 8 weeks (for new patients). NICE has not issued any guidance. Double Red Colesevelam HCl ▼ (Cholestagel® ▼) ICB Hypercholesterolaemia - as per NICE CG 181 Do Not Do Not recommended for routine use CG181 - Jul 14 Double Red Colesevelam hydrochloride (Cholestagel®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do Not recommended for routine use CG181 - Jul 14 Hospital Colestilan () NHSE Management of hyperphosphataemia in adults on renal dialysis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Colestipol hydrochloride (Colestid®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Double Red Colestyramine (Questran®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Hospital Colistimethate sodium (nebulised) (Colomycin®, Promixin®) NHSE Pseudomonas lung infection in Cystic Fibrosis (new patients from 1st April 2013) - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 AMB Colistimethate sodium (Nebulised) (Colomycin®, Promixin®) ICB Ps. aeurginosa infection in non-Cystic Fibrosis bronchiectasis Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. Hospital Colistimethate sodium Dry Powder Inhaler (Colobreathe® Dry Powder Inhaler) NHSE Pseudomonas lung infection in cystic fibrosis - as per NICE TA 276 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 DM Collagenase clostridium histolyticum (Xiapex®) ICB Dupuytren's contracture with a palpable cord in adults - as per NICE TA 459 Discontinued Medicines TA459 - Jul 17
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Clomethiazole (Heminevrin®) PHE Community-based assisted alcohol withdrawal - as per NICE CG 115 - Do Not Do Not recommended for routine use CG115 - Feb 11 GREEN Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Prevention of atherosclerotic events Formulary - Drugs that can be initiated by Prescriber in Primary Care TA210 - Dec 10 Hospital Factor X Clopidogrel (CoagadexPlavix®, generics approved for use - Sept 2009) NHSE Hereditary factor X deficiency ICB Prophylaxis pre-elective PCI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB Acute Coronary Syndrome without ST- segment elevation (NSTEMI) (with aspirin) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script. TA80 - Jul 04 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB Post elective percutaneous coronary intervention (PCI) - bare metal stent (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in-patient stay. NICE has not issued any guidance. ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB ST-elevation myocardial infarction (STEMI) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in patient stay; max one month. NICE has not issued any guidance. Hospital Factor XIII Clozapine (Clozaril®, Denzapine®, Zaponex®) ICB Schizophrenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG82 - Mar 09 Hospital Cobicistat ▼ (Tybost® ▼) NHSE Specialist indications Use as a booster in treatment of HIV positive adults and adolescents - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Cobimetinib ▼ (in combination with vemurafenib) (Cotellic® ▼) NHSE Unresectable or metastatic BRAF V600 mutation-positive melanoma - as per NICE TA 414 Not commissioned. No NHS prescribing in primary or secondary care TA414 - Oct 16 Hospital Co-careldopa intestinal gel (Duodopa® ▼) NHSE Severe Xxxxxxxxx'x disease inadequately controlled by other preparations - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Cochlear implants (FEIBAVarious) NHSE For children and adults with severe to profound deafness - specialist commissioned use only as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA566 - Mar 19 Double Red Codeine linctus generic ICB Cough suppressant Not recommended for routine use NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance BLACK Co-enzyme Q10 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 17 BLACK Co-enzyme Q11 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 GREEN Colecalciferol (Vitamin D) (Licensed Vitamin D products) ICB Treatment of vitamin D deficiency in adults and children - as per local policies Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. BLACK Colecalciferol (Vitamin D) (Various) ICB To increase adherence to statin treatment - as per NICE CG 181 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 14 ADVICE Colesevelam HCl (Cholestagel®) ICB Third-line option for (unlicensed) use in bile salt malabsorption causing diarrhoea (for patients under the NNUH only) (Not a licensed indication). Formulary - Specialist indications advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 8 weeks (for new patients). NICE has not issued any guidance. Double Red Colesevelam HCl ▼ (Cholestagel® ▼) ICB Hypercholesterolaemia - as per NICE CG 181 Do Not Do Not recommended for routine use CG181 - Jul 14 Double Red Colesevelam hydrochloride (Cholestagel®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do Not recommended for routine use CG181 - Jul 14 Hospital Colestilan () NHSE Management of hyperphosphataemia in adults on renal dialysis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate Colestipol hydrochloride (Lipantil®; Supralip®; CholibColestid®) ICB Prevention of CVD CVD, alone or added to a statin - as per NICE CG 181 "- Do Not Do" Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Double Red Colestyramine (Questran®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays Hospital Colistimethate sodium (Effentoranebulised) (Colomycin®, Actiq®, Instanyl®, PecFentPromixin®) ICB NHSE Pseudomonas lung infection in Cystic Fibrosis (Acutenew patients from 1st April 2013) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 AMB Colistimethate sodium (Nebulised) (Colomycin®, Promixin®) ICB Ps. aeurginosa infection in non-Cystic Fibrosis bronchiectasis Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. Double Red Filibuvir Hospital Colistimethate sodium Dry Powder Inhaler (Colobreathe® Dry Powder Inhaler) NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease Pseudomonas lung infection in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis cystic fibrosis - as per NICE TA 254 276 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 TA276 - Apr 12Mar 13 DM Collagenase clostridium histolyticum (Xiapex®) ICB Dupuytren's contracture with a palpable cord in adults - as per NICE TA 459 Discontinued Medicines TA459 - Jul 17 DM Collagenase Clostridium Histolyticum (Xiapex®) ICB Peyronie’s Disease Discontinued Medicines NICE has not issued any guidance. BLACK Combination analgesics with caffeine () ICB Pain relief Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Factor XIII Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE Specialist indications HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor HIV/AIDS treatments (FEIBAVarious) NHSE Specialist indications HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Fampridine Hormone Replacement Therapy (Fampyra®HRT) NHSE Improvement - systemic (Various) ICB Treatment of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) urinary incontinence - as per NHS England policy NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat CG171 - Nov 15 NF HRT implants (Adenuric®Various) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE diseaseHormone replacement therapy Non-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – February 2021 March 2024 Hospital Filgotinib Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Paediatric indications (where adult TA available) - specialist centres only Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE Xxxxx Syndrome As per National Demand Management Plan - specialist centres only NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim Human Normal Immunoglobulin (Various ▼Flebogamma®) (Flebogamma®) NHSE Reduction As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - as per NHS England NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) As per National Demand Management Plan - NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - Apr 12NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted ADVICE Chloral hydrate 500mg/5ml oral solution n/a ICB off-label use – Prescribing in treatment of dystonia Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to remain with the hospital or specialist service. No prescribing in primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication RED Chlorambucil (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraLeukeran®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin BLACK Chlorhexidine Mouthwash (Dificlir®Various) ICB Treatment prophylaxis against infective endocarditis to people at risk of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation infective endocarditis undergoing dental procedures - as per local policy Formulary NICE CG 64 - Specialist advice required from Do Not Do Not commissioned. No NHS prescribing in primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis CG64 - Jul 16 RED Chlormethine gel Ledaga® NHSE mycosis fungoides-type cutaneous T-cell lymphoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 TA720 – February August 2021 Hospital Filgotinib DM Chlorpropamid e () ICB Type 2 diabetes mellitus Discontinued Medicines NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Cholesterol and Simvastatin cream n/a ICB disseminated superficial actinic porokeratosis Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. RED Cholic acid (Orphacol®, Kolbam®) NHSE Paediatric indications (where adult TA available) - specialist centres only Inborn errors in primary bile acid synthesis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® BLACK Chondroitin (Various) ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist serviceOsteoarthritis - as per NICE CG 177 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care TA792 – June 2022 Hospital Filgrastim CG177 - Feb 14 ADVICE Ciclosporin (Ikervis®) ICB Severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes (Consultant recommendation only) - as per NICE TA 369 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA369 - Dec 15 SCA Ciclosporin (Various brands - to be specified by prescribers) ICB Rheumatic and dermatological diseases. Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NG100 - Jul 18 RED Cidofovir (Vistide®) NHSE Xxxxx Syndrome - specialist centres only Cytomegalovirus (CMV) infection Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim BLACK Cilostazol (Various ▼Pletal®) NHSE Reduction ICB Treatment of intermittent claudication in the duration of neutropenia and the incidence of febrile neutropenia in patients treated people with established cytotoxic chemotherapy for malignancy peripheral arterial disease - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service223 Not commissioned. No NHS prescribing in primary or secondary care TA254 TA223 - Apr 12May 11 BLACK Ciltacabtagene autoleucel n/a NHSE relapsed or refractory multiple myeloma Not commissioned. No NHS prescribing in primary or secondary care TA889 – May 2023
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Gevokizumab (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Gilteritinib Xospata® NHSE relapsed or refractory acute myeloid leukaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA642 – August 2020 Hospital Givosiran Givlaari NHSE Hepatic porphyria Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST16 - Nov 2021 BLACK Glasdegib (FEIBA) NHSE Specialist indications with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA646 – September 2020 Hospital Glatiramer (Copaxone®) NHSE Multiple Sclerosis - as per NICE TA 527 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA527 - Jun 18 Hospital Glecaprevir-pibrentasvir ▼ (Maviret® ▼) NHSE Chronic hepatitis C Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA499 - Jan 18 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance DM Glibenclamide (Various eg Daonil®, Euglucon®) ICB Type 2 diabetes mellitus Discontinued Medicines NICE has not issued any guidance. BLACK Gliclazide modified release (Diamicron® MR) ICB Type 2 diabetes mellitus Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Glofitamab Columvi® NHSE relapsed or refractory diffuse large B- cell lymphoma after 2 or more systemic treatments Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA927 – October 2023 Hospital Glucarpidase (Voraxase) NHSE Urgent treatment of methotrexate- induced renal dysfunction in patients receiving high-dose MTX chemotherapy - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine Glucocorticoids (Fampyra®inc hydrocortisone, prednisolone) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7Generics are available) ICB Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do Not commissioned. No NHS England policy prescribing in primary or secondary care CG53 - Aug 07 BLACK Glucosamine (Various) ICB Osteoarthritis - as per NICE CG 177 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG177 - Feb 14 BLACK Glucosamine, Glucosamine & Chondroitin (Alateris and various) ICB Osteoarthritis Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK FarcoGluten-fill Protect free foods (Various) ICB Indwelling urinary catheterisation Gluten sensitive enteropathies in all patients across N+W Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol Glycerol phenylbutyrate (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other Ravicti® 1.1 g/ml oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealantsliquid) NHSE Haemostatic / tissue glue Urea cycle disorders (specialist use only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried GlycoPEGylated Factor IX (Human) (Rebinyn®) NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Haemophilia B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Botulinum Toxin Type A (CoagadexDysport®) ICB Muscle spasticity in neuromuscular conditions - cerebral palsy - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Botulinum Toxin Type A (Botox®, Dysport®) ICB Treatment of focal spasticity in Multiple Sclerosis or following stroke or brain injury - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Botulinum Toxin Type A and B (Botox®) NHSE Hereditary factor X deficiency Intravesical use in spinal cord injury Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII Botulinum Toxin Type A and B (Botox®) NHSE Specialist indications Focal spasticity in children Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Brentuximab vedotin (FEIBAAdcetris®) NHSE Specialist indications CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease - as per NICE TA 524 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA524 - Jun 18 Hospital Brentuximab vedotin (Adcetris®) NHSE Treating CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome - as per NICE TA 577 (NHSE comm Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA577 - Apr 19 BLACK Brentuximab vedotin (Adcetris®) NHSE Untreated advanced Hodgkin lymphoma (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA594 - Aug 19 Hospital Brentuximab vedotin (Adcetris®) NHSE in combination for untreated systemic anaplastic large cell lymphoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA641 – August 2020 Hospital Brentuximab vedotin ▼ (Adcetris® ▼) NHSE CD30-positive Hodgkin lymphoma - as per NICE TA 446 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA446 - Jun 17 Hospital Brentuximab vedotin ▼ (Adcetris® ▼) NHSE For treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - as per NICE TA 478 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA478 - Oct 17 Hospital Brexucabtagene autoleucel Tecartus® NHSE relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA893 – June 2023 Hospital Brigatinib (Alunbrig®) NHSE For treating ALK-positive advanced non- small-cell lung cancer in adults, after crizotinib - as per NICE TA 571 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA571 - Mar 19 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Brigatinib Alunbrig® NHSE ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA670 – January 2021 Hospital Brimapitide NHSE Acute sensorineural hearing loss Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine Brimonidine tartrate gel (FampyraMirvaso®) NHSE Improvement ICB Treatment of walking in adults with Multiple Sclerosis with walking disability facial erythema (EDSS 4-7rosacea) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat Brincidofovir (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indicationCMX001). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications CMV infection Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) Brivaracetam Briviact ICB Treatment of mild epilepsy as alternative to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy levetiracetam Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication Hospital Brodalumab (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib JyselecaKyntheum®) ICB Moderate to severe rheumatoid arthritis plaque psoriasis - as per NICE TA 511 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 TA511 - Mar 18 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Brolucizumab Beovu® ICB Wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib JyselecaTA672 – February 2021 BLUE Brolucizumab Beovu® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes diabetic macular oedema NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ TA820 – August 2022 BLACK Bromocriptine (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis ICB Pharmacological neuroprotective therapy in Xxxxxxxxx'x disease (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Bromocriptine mesilate (Parlodel®) ICB First-line use in Xxxxxxxxx'x disease - as per NICE TA 254 NG 17 Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 ADVICE Budenofalk (Budenofalk®) ICB Crohn's disease in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. ADVICE Budenofalk (Budesonide 3mg caps & 9mg granules) (Budenofalk®) ICB Collagenous colitis in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Budesonide (oral viscous slurry) Pulmicort respules ICB eosinophilic oesophagitis in adults and paediatrics Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 NICE has not issued any guidance BLACK Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults - Apr 12treatment for maintenance of remission Not commissioned. No NHS prescribing in primary or secondary care TA708 – June 2021 ADVICE Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (GP may issue a SINGLE follow-up treatment (NOT for repeat) only if deemed necessary following assessment of response to initial treatment by given the hospital) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. TA708 – June 2021 Hospital Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (first treatment with follow-up assessment of effectiveness by the hospital) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA708 – June 2021 Hospital Bulevirtide Hepcludex® NHSE chronic hepatitis D Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA896 – June 2023 GREEN Buprenorphine (sublingual & oral lyophilisate) (Subutex® - generics available / Espranor®) NCC Opioid dependence (for use by prescribers with competence in treating opioid dependence) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. ADVICE Buprenorphine (transdermal) (Butec®, Transtec® patches) ICB Patients with renal impairment (eGFR 15- 30, CKD 4) who have an accumulation of opiates and a resulting potential for toxicity Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLUE Buprenorphine Long- Acting Injection Buvidal®) ICB opioid substitution treatment NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required RMOC - April 2021 GREEN Bupropion (Zyban®) NCC Adjunct to smoking cessation Formulary - Drugs that can be initiated by Prescriber in Primary Care NG92 - Mar 18 Hospital Burosumab (Crysvita®) NHSE X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in young people with growing bones - as per NICE HST 8 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST8 - Oct 18 Double Red Buspirone (Generics are available) ICB Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do Not recommended for routine use CG90 - Oct 09 Hospital Busulfan (Myleran®) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Butyrophenones (benperidol and haloperidol) (Various) ICB NICE Do Not Do - Use in Xxxxxxxxx'x disease - as per NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Hospital C1 Esterase Inhibitors NHSE Hereditary angioedema treatment and prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Cabazitaxel (Jevtana®) NHSE Hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen - as per NICE TA 255 Not commissioned. No NHS prescribing in primary or secondary care TA255 - May 12 Hospital Cabazitaxel (Jevtana®) NHSE Metastatic hormone relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy - as per NICE TA 391 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA391 - Aug 16 BLACK Cabergoline (Cabaser®) ICB First-line use in Xxxxxxxxx'x disease - as per NICE NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Cabotegravir Vocabria® NHSE HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Cabotegravir Vocabria® NHSE with rilpivirine for treating HIV-1 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA757 – January 2022 Hospital Cabozantinib (Cometriq®) NHSE For treating medullary thyroid cancer - as per NICE TA 516 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA516 - Mar 18 Hospital Cabozantinib (Cabometyx®) NHSE Untreated advanced renal cell carcinoma in adults under defined circumstances - as per NICE TA 542 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA542 - Oct 18 Hospital Cabozantinib Cabometyx® NHSE previously treated advanced hepatocellular carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA849 – December 2022 BLACK Cabozantinib Cabometyx® NHSE previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine Not commissioned. No NHS prescribing in primary or secondary care TA928 – November 2023 Hospital Cabozantinib Cabometyx® NHSE with nivolumab for untreated advanced renal cell carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA964 – April 2024 Hospital Cabozantinib ▼ (Cabometyx® ▼) NHSE Previously treated advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)- targeted therapy - as per NICE TA 463 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA463 - Aug 17 Hospital Calcifidiol NHSE Inborn errors in primary bile acid synthesis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Calcium and Ergocalciferol combi tablets (Generic tablets) ICB Prevention of osteoporosis-related fractures and falls Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Double Red Calcium channel blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 - NICE Do Not Do Not recommended for routine use CG101 - Jul 10
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X SCA Anagrelide ▼ (CoagadexXagrid® ▼ / Agrelin® / Agrylin®) ICB Thrombocythaemia Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Anakinra Kineret® NHSE Still’s disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA685 – March 2021 RED Anakinra (Kineret®) NHSE Hereditary factor X deficiency Cryopyrin-associated periodic syndrome (CAPS) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Anakinra (Kineret®) NHSE Adult onset Still's disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Anakinra (Kineret®) NHSE Rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NG100 - Oct 2020 RED Anakinra (Kineret®) NHSE Juvenile Idiopathic Arthritis (JIA) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Anakinra (Kineret®) NHSE Periodic fevers and autoinflammatory conditions Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Anastrozole (Arimidex®) ICB Breast cancer - as per NICE CG81 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 ADVICE Anastrozole (Arimidex®) ICB Post menopausal Women at moderate or High or moderate risk of breast Cancer unless they have severe osteoporosis Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG164 - updated Nov 2019 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Andexanet alfa Ondexxya® ICB for reversing anticoagulation from edoxaban Not commissioned. No NHS prescribing in primary or secondary care TA697 – May 2021 RED Andexanet alfa Ondexxya® ICB for reversing anticoagulation from apixaban or rivaroxaban Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA697 – May 2021 BLACK Angiotensin II Giapreza® ICB vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA859 – Jan 2023 Double Red Angiotensin-II receptor antagonists with ACE inhibitors (Various) ICB with ACE inhibitors (Not a licensed indication). Not recommended for routine use CG182 - Jul 14 RED Anidulafungin (Ecalta®) NHSE Fungal infection - invasive candidiasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Anifrolumab N/A NHSE active autoantibody-positive systemic lupus erythematosus (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA793 – June 2022 Double Red Antacids - various (Various) ICB Long term frequent use in functional dyspepsia - as per NICE CG 184 - Do Not Do Not recommended for routine use CG184 - Aug 04 Double Red Antibiotic prophylaxis (Various) ICB Infective endocarditis and interventional procedure (dental/non dental) - as per NICE CG 64 Not recommended for routine use CG64 - Jul 16 RED Antibiotics - intravenous / inhalation (Various) NHSE Cystic fibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Double Red Antibiotics (oral for children) (Various) ICB Fever in children without apparent source - as per NICE CG 160 - Do Not Do Not recommended for routine use NG143 - Nov 19 GREEN Anticoagulant monitoring self test strips (Various (e.g. CoaguChek)) ICB Anticoagulant self testing Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. RED Anti-D immunoglobuli n (Various) ICB Routine anti-D prophylaxis (RAADP) - as per NICE TA 156 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA156 - Aug 08 Double Red Antidepressant s (including SSRIs) (Various) ICB (Routine use) for the treatment of alcohol misuse alone - as per NICE CG 115 - Do Not Do Not recommended for routine use CG115 - Feb 11 RED Antihaemophili c Factor XIII ((von Willebrand Factor Complex)) NHSE Specialist indications As per BCSH Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Bevacizumab (CoagadexAvastin®) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications ICB Radiation retinopathy macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Bexarotene (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraTargretin®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin Double Red Bezafibrate (DificlirBezalip; Fibrazate) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" Not recommended for routine use CG181 - Jul 14 BLACK Bezlotoxumab (Zinplava®) ICB Treatment Prevention of mild to moderate C. recurrent clostridium difficile infection (CDIterminated appraisal) Not commissioned. No NHS prescribing in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician TA601 - Sep 19 Hospital Bictecravir (in combination with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless statedemtricitabine and tenofivir alafenamide) Instructions for Prescriber NICE Guidance Hospital Filgotinib JyselecaBiktarvy ®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim Bimagrumab ((BYM338)) NHSE Xxxxx Syndrome - specialist centres only Inclusion body myositis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim Bimekizumab Bimzelx® ICB active psoriatic arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA916 – October 2023 Hospital Bimekizumab Bimzelx® ICB axial spondyloarthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA918 – October 2023 Hospital Bimekizumab Bimzelx® ICB moderate to severe plaque psoriasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA723 – September 2021 Traffic Light Classification Drug Name Brand Name Commissione r Indication (Various ▼assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Binimetinib (Mektovi®) NHSE Reduction (with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy adults - as per NICE TA 562 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA562 - Feb 19 BLACK Bioidentical HRT (Bioidentical hormone replacement therapy) ICB Menopausal symptoms Not commissioned. No NHS England policy prescribing in primary or secondary care NG23 - Nov 13 Hospital Biotin (vitamin H) (Qizenday®, Cerenday®, MD1003) NHSE various Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () Hospital Birch bark extract n/a NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 epidermolysis bullosa Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 HST28 – September 2023 Hospital Bivalirudin (Angiox®) ICB Treatment of ST-segment-elevation myocardial infarction - Apr 12as per NICE TA 230 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA230 - Jul 11 Hospital Blinatumomab (Blincyto®) NHSE Acute lymphoblastic leukaemia in remission with minimal residual disease activity Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA589 - Jul 19 BLACK Blinatumomab N/A NHSE previously treated Philadelphia- chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA686 – March 2021 Hospital Blinatumomab ▼ (Blincyto® ▼) NHSE Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults - as per NICE TA 450 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA450 - Jun 17 Hospital Blisibimod () NHSE Systemic lupus erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Gevokizumab (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Gilteritinib Xospata® NHSE relapsed or refractory acute myeloid leukaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA642 – August 2020 Hospital Givosiran Givlaari NHSE Hepatic porphyria Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST16 - Nov 2021 BLACK Glasdegib (FEIBA) NHSE Specialist indications with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA646 – September 2020 Hospital Glatiramer (Copaxone®) NHSE Multiple Sclerosis - as per NICE TA 527 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA527 - Jun 18 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Glecaprevir- pibrentasvir ▼ (Maviret® ▼) NHSE Chronic hepatitis C Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA499 - Jan 18 DM Glibenclamide (Various eg Daonil®, Euglucon®) ICB Type 2 diabetes mellitus Discontinued Medicines NICE has not issued any guidance. BLACK Gliclazide modified release (Diamicron® MR) ICB Type 2 diabetes mellitus Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Glofitamab Columvi® NHSE relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA927 – October 2023 Hospital Glucarpidase (Voraxase) NHSE Urgent treatment of methotrexate- induced renal dysfunction in patients receiving high-dose MTX chemotherapy - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine Glucocorticoids (Fampyra®inc hydrocortisone, prednisolone) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7Generics are available) ICB Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do Not commissioned. No NHS England policy prescribing in primary or secondary care CG53 - Aug 07 BLACK Glucosamine (Various) ICB Osteoarthritis - as per NICE CG 177 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG177 - Feb 14 BLACK Glucosamine, Glucosamine & Chondroitin (Alateris and various) ICB Osteoarthritis Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK FarcoGluten-fill Protect free foods (Various) ICB Indwelling urinary catheterisation Gluten sensitive enteropathies in all patients across N+W Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol Glycerol phenylbutyrate (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other Ravicti® 1.1 g/ml oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealantsliquid) NHSE Haemostatic / tissue glue Urea cycle disorders (specialist use only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried GlycoPEGylated Factor IX (Human) (Rebinyn®) NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Haemophilia B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidanceTA47 - Sep 02 Hospital Eptinezumab VYEPTI® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA871 – March 2023 Hospital Factor X Eptotermin alfa (Coagadex) NHSE Hereditary factor X deficiency Complex spinal surgery Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Erectile dysfunction drugs (Various) ICB Erectile dysfunction - limited categories of patients under SLS for certain drugs Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Factor XIII NHSE Specialist indications Erectile dysfunction drugs (Various) ICB Severe distress from erectile dysfunction seeking treatment on the NHS Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab VabysmoBLUE Erenumab Aimovig® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes Preventing migraine NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- TA682 – March 2023 2021 Hospital Fingolimod ▼ Eribulin (Gilenya® ▼Halaven®) NHSE Highly active relapsing remitting multiple sclerosis Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens only when it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine) - as per NICE TA 254 423 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 TA423 - Apr 12Dec 16 Hospital Eribulin (Halaven®) NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 423 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 BLACK Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 1 chemotherapy regimen - as per NICE TA 515 Not commissioned. No NHS prescribing in primary or secondary care TA515 - Mar 18 BLACK Erlotinib (Tarceva®) NHSE Monotherapy for maintenance treatment of non-small-cell lung cancer - as per NICE TA 227 and NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA227 - Jun 11 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Erlotinib (Tarceva®) NHSE First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer - as per NICE TA 258 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA258 - Jun 12 BLACK Erlotinib (Tarceva®) NHSE Treatment of non-small-cell lung cancer (NSCLC) as per NICE TA 374 - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 BLACK Erlotinib (Tarceva®) NHSE Treating locally advanced or metastatic NSCLC that doesn’t test positive for the EGFR TK mutation (as per NICE TA 374) (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 ADVICE Ertugliflozin (Steglatro®) ICB As monotherapy or with metformin for treating type 2 diabetes - as per NICE TA 572 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA572 - Mar 19 GREEN Ertugliflozin (Steglatro®) ICB With metformin and a depeptidyl peptidase-4 inhibitor for Type 2 diabetes Formulary - Drugs that can be initiated by Prescriber in Primary Care TA583 - Jun 19 Hospital Erythropoietin (epoetin / darbepoetin) (Various) ICB Treatment of anaemia in people with cancer having chemotherapy - as per NICE TA 323 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA323 - Nov 14 Hospital Erythropoietin / Epoetin (Eprex) ICB Treatment of transfusion-dependent anaemia in myelodysplasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Erythropoietin / Epoetin (Eprex®, NeoRecormon® and others) NHSE Dialysis-induced anaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG114 - Nov 11 Double Red Erythropoietin / Epoetin (Eprex®, NeoRecormon® and others) ICB Anaemia in renal failure pre-dialysis. Not recommended for routine use NG8 - Jun 15 BLACK Esketamine Spravato® ICB nasal spray for treatment-resistant depression Not commissioned. No NHS prescribing in primary or secondary care TA854 – December 2022
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA29 - Sep 01 BLACK Fludarabine (Fludara®) NHSE B-cell Chronic Lymphocytic Leukaemia - 1st line treatment - as per NICE TA 119 Not commissioned. No NHS prescribing in primary or secondary care TA119 - Feb 07 ADVICE Fludroxycortide tape (previously Haelan) ICB Adjunctive therapy for chronic, localised, recalcitrant dermatoses that may respond to topical corticosteroids and particularly dry, scaling lesions Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidanceguidance BLACK Fludroxycortide tape (previously Haelan) ICB All unlicensed uses including hypertrophic scars and keloids Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance Hospital Factor X Fluocinolone acetonide intravitreal implant (CoagadexIluvien®) NHSE Hereditary factor X deficiency ICB Recurrent non-infectious uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication TA590 - Jul 19 Hospital Fluocinolone acetonide intravitreal implant (assume licensed unless statedreplaced 2 above) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications (Iluvien®) ICB chronic diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA953 – March 2024 Hospital FactorR VIII Inhibitor Bypassing Factor Fluoride supplements - Toothpaste; dental products (FEIBADuraphat 0.619% DPF; 1.1% DPF Toothpaste) NHSE Specialist indications ICB Prevention of dental caries in at-risk patients (where the specialist is a dentist) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine Folic acid (Fampyra®Generics are available) NHSE Improvement ICB Secondary prevention of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) MI / reduce cardiovsacular risk post MI - as per NHS England policy NICE CG 172 - Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG172 - Nov 13 BLACK Folic Acid (Generics are available) ICB For preventing hypertensive disorders during pregnancy - as per NICE has not issued any guidanceCG 107 - Do Not Do (Not a licensed indication). BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 CG107 - Aug 10 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat Fomepizole (AdenuricAntizol®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No Methanol and ethylene glycol poisoning (Poison Centre prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®only) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Arimoclomol NHSE Xxxxxxx Pick disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Aripiprazole (CoagadexAbilify®) ICB Moderate to severe manic episodes in adolescents with bipolar I disorder - as per NICE TA 292 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA292 - Jul 13 ADVICE Aripiprazole (Abilify®) ICB Schizophrenia and bipolar mood disorder - as per NICE CG 82 and TA 213 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG82 - Mar 09 BLACK Armour Thyroid / any unlicensed thyroid products (Armour Thyroid) ICB Any indication Not commissioned. No NHS prescribing in primary or secondary care RMOC guidance - June 2019 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Aromatase inhibitors (Various) (Various) ICB Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in post menopausal women - as per local protocol Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 Hospital Arsenic trioxide (Trisenox®) NHSE Hereditary factor X deficiency Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR- alpha gene) in adults - as per NICE TA 526 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA526 - Jun 18 GREEN Artificial saliva or salivary stimulants (Xerotin Oral spray or other cost-effective product) ICB Xerostomia from any cause where simple measures alone have been ineffective Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Asciminib Scemblix® NHSE chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA813 – August 2022 Hospital Asfotase alfa Strensiq® NHSE paediatric-onset hypophosphatasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST23 – March 2023 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Double Red Asunaprevir (with Daclatasvir) () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. Hospital Atacicept () NHSE Systemic Lupus Erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Ataluren ▼ (Translarna® ▼) NHSE Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged ≥5 years who can walk - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST22 - Feb 2023 Hospital Atazanavir (Reyataz®) NHSE HIV infection in combination with other antiretroviral drugs - as per BHIVA Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Atazanavir and Cobicistat (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraEvotaz®) NHSE Improvement of walking HIV infection in adults combination with Multiple Sclerosis with walking disability (EDSS 4-7) other antiretroviral drugs - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH BHIVA guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 Atezolizumab (FGF1) gene therapy (Tecentriq®) NHSE All indications Locally advanced or metastatic non- small-cell lung cancer after chemotherapy - as per NICE TA 520 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin TA520 - May 18 Hospital Atezolizumab (DificlirTecentriq®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation NHSE Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis TA 525 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 TA525 - Jun 18 Hospital Filgotinib () Atezolizumab Tecentriq® NHSE Paediatric indications (where adult TA available) - specialist centres only monotherapy for untreated advanced non-small-cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA705 – June 2021 Hospital Filgotinib JyselecaAtezolizumab Tecentriq® ICB moderately to severely active ulcerative colitis NHSE untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 TA739 – June 2022 October 2021 BLACK Atezolizumab TECENTRIQ® NHSE with carboplatin and nab-paclitaxel for untreated advanced non-squamous non- small-cell lung cancer as per TA618 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA618 - Jan 20 Hospital Filgrastim () Atezolizumab Tecentriq® NHSE Xxxxx Syndrome - specialist centres only adjuvant treatment of resected non-small cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA823 – October 2022 Hospital Filgrastim Atezolizumab▼ (Various Tecentriq® ▼) NHSE Reduction in the duration of neutropenia with carboplatin and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy etoposide for malignancy - as per NHS England policy untreated extensive-stage small-cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 TA638 - July 2020 Hospital Fingolimod Atezolizumab▼ (GilenyaTecentriq® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 with nab-paclitaxel for untreated PD-L1- positive, locally advanced or metastatic, triple-negative breast cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 TA639 - Apr 12July 2020 Hospital Atezolizumab▼ (Tecentriq® ▼) NHSE with bevacizumab for treating advanced or unresectable hepatocellular carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA666 – December 2020
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Bevacizumab (Avastin®) ICB Radiation retinopathy macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Bexarotene (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraTargretin®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin Double Red Bezafibrate (DificlirBezalip; Fibrazate) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" Not recommended for routine use CG181 - Jul 14 BLACK Bezlotoxumab (Zinplava®) ICB Treatment Prevention of mild to moderate C. recurrent clostridium difficile infection (CDIterminated appraisal) Not commissioned. No NHS prescribing in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician TA601 - Sep 19 Hospital Bictecravir (in combination with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless statedemtricitabine and tenofivir alafenamide) Instructions for Prescriber NICE Guidance Hospital Filgotinib JyselecaBiktarvy ®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim Bimagrumab ((BYM338)) NHSE Xxxxx Syndrome - specialist centres only Inclusion body myositis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim Bimekizumab Bimzelx® ICB active psoriatic arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA916 – October 2023 Hospital Bimekizumab Bimzelx® ICB axial spondyloarthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA918 – October 2023 Hospital Bimekizumab Bimzelx® ICB moderate to severe plaque psoriasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA723 – September 2021 Hospital Binimetinib (Various ▼Mektovi®) NHSE Reduction (with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy adults - as per NICE TA 562 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA562 - Feb 19 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Bioidentical HRT (Bioidentical hormone replacement therapy) ICB Menopausal symptoms Not commissioned. No NHS England policy prescribing in primary or secondary care NG23 - Nov 13 Hospital Biotin (vitamin H) (Qizenday®, Cerenday®, MD1003) NHSE various Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () Hospital Birch bark extract n/a NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 epidermolysis bullosa Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 HST28 – September 2023 Hospital Bivalirudin (Angiox®) ICB Treatment of ST-segment-elevation myocardial infarction - as per NICE TA 230 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA230 - Jul 11 Hospital Blinatumomab (Blincyto®) NHSE Acute lymphoblastic leukaemia in remission with minimal residual disease activity Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA589 - Jul 19 BLACK Blinatumomab N/A NHSE previously treated Philadelphia- chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA686 – March 2021 Hospital Blinatumomab ▼ (Blincyto® ▼) NHSE Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults - as per NICE TA 450 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA450 - Jun 17 Hospital Blisibimod () NHSE Systemic lupus erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Boceprevir (Victrelis®) NHSE Treatment of genotype 1 chronic hepatitis C - as per NICE TA 253 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA253 - Apr 1212 Hospital Bortezomib (Velcade®) NHSE Multiple myeloma (first line) - as per NICE 228 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA228 - Jul 11
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X RED Atidarsagene autotemcel Libmeldy NHSE metachromatic leukodystrophy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST18 - March 2022 ADVICE Atogepant Aquipta® ICB preventing migraine Specialist will initiate and provide the first 12 weeks of medication to the patient. TA973 – May 2024 SCA Atomoxetine (CoagadexStrattera®) ICB Attention Deficit Hyperactivity Disorder in Adults for new treatment of symptoms that can be confirmed from childhood Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly NG87 - Mar 18 SCA Atomoxetine (currently under review) (Strattera® ▼) ICB Attention Deficit Hyperactivity Disorder in Children & Adolescents Shared Care Agreement Level 3 - Prescribe the drug and perform significant monitoring including measurements such as height, weight, blood pressure and ECG NG87 - Mar 18 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Atypical antipsychotics (except clozapine) (Various (except Clozaril® (Red)) ICB Psychosis and schizophrenia in adults - As per NICE CG 178 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of one month. CG82 - Mar 09 GREEN Auto inflation device (Otovent) (Otovent®) ICB Considered use for equalisation of pressure in the middle ear: in otitis media with effusion (glue ear) in children who are able to cooperate with treatment. Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. RED Autologous anti-CD19- transduced CD3+ cells Tecartus® NHSE Relapsed or refractory mantle cell lymphoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA677 – February 2021 RED Autologous chondrocyte implantation (Spherox®) NHSE Hereditary factor X deficiency For treating symptomatic articular cartilage defects of the knee - as per NICE TA 508 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA508 - Mar 18 RED Autologous serum eye drops () NHSE Dry eye Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII RED Avacopan Tavneos® NHSE Specialist indications Anca-positive vasculitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) RED Avacopan Tavneos® NHSE Specialist indications severe active granulomatosis with polyangiitis or microscopic polyangiitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA825 – September 20 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE has not issued any guidanceGuidance RED Avalglucosidas e alfa AVAL® NHSE Pompe disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA821 – August 2022 BLACK Fampridine Avanafil ▼ (Fampyra®Spedra® ▼) NHSE Improvement ICB Use of walking regular, daily doses for penile rehabilitation in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy prostate cancer/post radical prostatectomy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Avapritinib N/A NHSE unresectable or metastatic gastrointestinal stromal tumours (terminated) Not commissioned. No NHS prescribing in primary or secondary care MIB 121 TA730 – September 2017 Hospital Faricimab Vabysmo® 2021 RED Avatrombopag (Doptelet®) ICB diabetic macular oedema treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab VabysmoTA626 - Jun 2020 RED Avatrombopag Doptelet® ICB wet age-related macular degeneration primary chronic immune thrombocytopenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 TA853 – June December 2022 GREEN Febuxostat RED Avelumab (AdenuricBavencio®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol NHSE Metastatic Xxxxxx cell carcinoma - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis 517 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® TA517 - Apr 18 RED Avelumab (Bavencio®) NHSE seizures associated with Dravet syndrome axitinib for untreated advanced renal cell carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 TA645 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care September 2020 RED Avelumab Bavencio® NHSE untreated metastatic Xxxxxx cell carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment TA691 – April 2021 RED Avelumab Bavencio® NHSE maintenance treatment of ironlocally advanced or metastatic urothelial cancer after platinum-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products based chemotherapy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use TA788 – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12May 2022
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Gevokizumab (Coagadex) NHSE Hereditary factor X deficiency Uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Gilteritinib Xospata® NHSE relapsed or refractory acute myeloid leukaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA642 – August 2020 Hospital Givosiran Givlaari NHSE Hepatic porphyria Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST16 - Nov 2021 BLACK Glasdegib () NHSE with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA646 – September 2020 Hospital Glatiramer (Copaxone®) NHSE Multiple Sclerosis - as per NICE TA 527 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA527 - Jun 18 Hospital Glecaprevir-pibrentasvir ▼ (Maviret® ▼) NHSE Chronic hepatitis C Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA499 - Jan 18 DM Glibenclamide (Various eg Daonil®, Euglucon®) ICB Type 2 diabetes mellitus Discontinued Medicines NICE has not issued any guidance. BLACK Gliclazide modified release (Diamicron® MR) ICB Type 2 diabetes mellitus Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII Glofitamab Columvi® NHSE Specialist indications relapsed or refractory diffuse large B- cell lymphoma after 2 or more systemic treatments Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA927 – October 2023 Hospital Glucarpidase (Voraxase) NHSE Urgent treatment of methotrexate- induced renal dysfunction in patients receiving high-dose MTX chemotherapy - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Glucocorticoids (inc hydrocortisone, prednisolone) (Generics are available) ICB Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG53 - Aug 07 BLACK Glucosamine (Various) ICB Osteoarthritis - as per NICE CG 177 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG177 - Feb 14 BLACK Glucosamine, Glucosamine & Chondroitin (Alateris and various) ICB Osteoarthritis Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Gluten-free foods (Various) ICB Gluten sensitive enteropathies in all patients across N+W Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Glycerol phenylbutyrate (Ravicti® 1.1 g/ml oral liquid) NHSE Urea cycle disorders (specialist use only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing GlycoPEGylated Factor IX (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraRebinyn®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Haemophilia B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) Glycopyrronium bromide Glycobromag ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Hyperhidrosis Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA29 - Sep 01 BLACK Fludarabine (Fludara®) NHSE B-cell Chronic Lymphocytic Leukaemia - 1st line treatment - as per NICE TA 119 Not commissioned. No NHS prescribing in primary or secondary care TA119 - Feb 07 ADVICE Fludroxycortide tape (previously Haelan) ICB Adjunctive therapy for chronic, localised, recalcitrant dermatoses that may respond to topical corticosteroids and particularly dry, scaling lesions Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidanceguidance BLACK Fludroxycortide tape (previously Haelan) ICB All unlicensed uses including hypertrophic scars and keloids Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor X Fluocinolone acetonide intravitreal implant (CoagadexIluvien®) NHSE Hereditary factor X deficiency ICB Treatment of chronic diabetic macular oedema after inadequate response to prior therapy - pseudophakic eye only - as per NICE TA 301 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA301 - Nov 13 Hospital Fluocinolone acetonide intravitreal implant (Iluvien®) ICB Recurrent non-infectious uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA590 - Jul 19 BLACK Fluocinolone acetonide intravitreal implant (Iluvien®) ICB Chronic diabetic macular oedema insufficiently responsive to available therapies in an eye with a natural lens (phakic eye) Not commissioned. No NHS prescribing in primary or secondary care TA613 - Nov 2019 Hospital Fluoride supplements - Toothpaste; dental products (Duraphat 0.619% DPF; 1.1% DPF Toothpaste) ICB Prevention of dental caries in at-risk patients (where the specialist is a dentist) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication BLACK Folic acid (assume Generics are available) ICB Secondary prevention of MI / reduce cardiovsacular risk post MI - as per NICE CG 172 - Do Not Do (Not a licensed unless statedindication). Not commissioned. No NHS prescribing in primary or secondary care CG172 - Nov 13 BLACK Folic Acid (Generics are available) Instructions for Prescriber ICB For preventing hypertensive disorders during pregnancy - as per NICE Guidance CG 107 - Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG107 - Aug 10 Hospital Factor XIII NHSE Specialist indications Fomepizole (Antizol®) ICB Methanol and ethylene glycol poisoning (Poison Centre prescribing only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Fondaparinux sodium (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraArixtra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage unstable angina or non- ST segment elevation myocardial infarction (UA/NSTEMI) in congenital hypofibrinogenaemia or afibrinogenaemia adults for whom urgent (< 120 mins) invasive management i.e. percutaneous coronary intervention (PCI) is not indicated - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England regional network policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 CG94 - Apr 12Mar 10
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X HIV/AIDS treatments (CoagadexVarious) NHSE Hereditary factor X deficiency HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE Specialist indications As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Human normal immunoglobulin (FEIBAIntratect®) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraIntratect®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) As per National Demand Management Plan - as per NHS England NHSE policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried Human normal immunoglobulin (HumanIVIg) (Privigen®) NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as As per BCSH guidelines National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 Human Normal Immunoglobulin (FGF1Kiovig) gene therapy (Kiovig®) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation As per National Demand Management Plan - as per local NHSE policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim Human Normal Immunoglobulin (Octagam) (Octagam®) NHSE Xxxxx Syndrome As per National Demand Management Plan - specialist centres only NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim Human Normal Immunoglobulin (Various ▼Subcuvia®) (Subcuvia®) NHSE Reduction As per National Demand Management Plan - NHSE Policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Subgam®) (Subgam®) NHSE As per National Demand Management Plan - as per NHS England NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir Hospital Human Normal Immunoglobulin (Vigam®) (Vigam®) NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) As per National Demand Management Plan - NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Vivaglobin®)) (Vivaglobin® (for s-c infusion) (discontinued 2011)) NHSE As per National Demand Management Plan - Apr 12NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) RED Arimoclomol NHSE Hereditary factor X deficiency Xxxxxxx Pick disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Aripiprazole (Abilify®) ICB Moderate to severe manic episodes in adolescents with bipolar I disorder - as per NICE TA 292 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA292 - Jul 13 ADVICE Aripiprazole (Abilify®) ICB Schizophrenia and bipolar mood disorder - as per NICE CG 82 and TA 213 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG82 - Mar 09 BLACK Armour Thyroid / any unlicensed thyroid products (Armour Thyroid) ICB Any indication Not commissioned. No NHS prescribing in primary or secondary care RMOC guidance - June 2019 ADVICE Aromatase inhibitors (Various) (Various) ICB Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in post menopausal women - as per local protocol Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII RED Arsenic trioxide (Trisenox®) NHSE Specialist indications Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha gene) in adults - as per NICE TA 526 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA526 - Jun 18 GREEN Artificial saliva or salivary stimulants (Xerotin Oral spray or other cost- effective product) ICB Xerostomia from any cause where simple measures alone have been ineffective Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. RED Asciminib Scemblix® NHSE chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA813 – August 2022 RED Asfotase alfa Strensiq® NHSE paediatric-onset hypophosphatasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST23 – March 2023 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Double Red Asunaprevir (with Daclatasvir) () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. RED Atacicept () NHSE Systemic Lupus Erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor RED Ataluren ▼ (FEIBATranslarna® ▼) NHSE Specialist indications Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged ≥5 years who can walk - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST22 - Feb 2023 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Atazanavir (Reyataz®) NHSE HIV infection in combination with other antiretroviral drugs - as per BHIVA Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine RED Atazanavir and Cobicistat (FampyraEvotaz®) NHSE Improvement of walking HIV infection in adults combination with Multiple Sclerosis with walking disability (EDSS 4-7) other antiretroviral drugs - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH BHIVA guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 RED Atezolizumab (FGF1) gene therapy (Tecentriq®) NHSE All indications Locally advanced or metastatic non- small-cell lung cancer after chemotherapy - as per NICE TA 520 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin TA520 - May 18 RED Atezolizumab (DificlirTecentriq®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation NHSE Locally advanced or metastatic urothelial carcinoma after platinum- containing chemotherapy - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis TA 525 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () TA525 - Jun 18 RED Atezolizumab Tecentriq® NHSE Paediatric indications (where adult TA available) - specialist centres only monotherapy for untreated advanced non-small-cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib JyselecaTA705 – June 2021 RED Atezolizumab Tecentriq® ICB moderately to severely active ulcerative colitis NHSE untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 TA739 – June 2022 Hospital Filgrastim October 2021 BLACK Atezolizumab TECENTRIQ® NHSE with carboplatin and nab-paclitaxel for untreated advanced non- squamous non-small-cell lung cancer as per TA618 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA618 - Jan 20 RED Atezolizumab Tecentriq® NHSE Xxxxx Syndrome - specialist centres only adjuvant treatment of resected non- small-cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use TA823 – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12October 2022
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA29 - Sep 01 BLACK Fludarabine (Fludara®) NHSE B-cell Chronic Lymphocytic Leukaemia - 1st line treatment - as per NICE TA 119 Not commissioned. No NHS prescribing in primary or secondary care TA119 - Feb 07 ADVICE Fludroxycortide tape (previously Haelan) ICB Adjunctive therapy for chronic, localised, recalcitrant dermatoses that may respond to topical corticosteroids and particularly dry, scaling lesions Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidanceguidance BLACK Fludroxycortide tape (previously Haelan) ICB All unlicensed uses including hypertrophic scars and keloids Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor X Fluocinolone acetonide intravitreal implant (CoagadexIluvien®) NHSE Hereditary factor X deficiency ICB Recurrent non-infectious uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA590 - Jul 19 Hospital Fluocinolone acetonide intravitreal implant (Iluvien®) ICB chronic diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA953 – March 2024 Hospital Fluoride supplements - Toothpaste; dental products (Duraphat 0.619% DPF; 1.1% DPF Toothpaste) ICB Prevention of dental caries in at-risk patients (where the specialist is a dentist) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication BLACK Folic acid (assume Generics are available) ICB Secondary prevention of MI / reduce cardiovsacular risk post MI - as per NICE CG 172 - Do Not Do (Not a licensed unless statedindication). Not commissioned. No NHS prescribing in primary or secondary care CG172 - Nov 13 BLACK Folic Acid (Generics are available) Instructions for Prescriber ICB For preventing hypertensive disorders during pregnancy - as per NICE Guidance CG 107 - Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG107 - Aug 10 Hospital Factor XIII NHSE Specialist indications Fomepizole (Antizol®) ICB Methanol and ethylene glycol poisoning (Poison Centre prescribing only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Fondaparinux sodium (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraArixtra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage unstable angina or non- ST segment elevation myocardial infarction (UA/NSTEMI) in congenital hypofibrinogenaemia or afibrinogenaemia adults for whom urgent (< 120 mins) invasive management i.e. percutaneous coronary intervention (PCI) is not indicated - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England regional network policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir CG94 - Mar 10 BLACK Fondaparinux sodium (Arixtra®) NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease Prophylaxis of venous thromboembolism in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification those undergoing major orthopaedic surgery of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis the legs - as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist serviceDoNotDo recommendation Not commissioned. No NHS prescribing in primary or secondary care TA254 NG89 - Apr 12Mar 18
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X RED Adalimumab (CoagadexHumira® / Biosimilar) NHSE Hereditary Children with Severe Refractory Uveitis with onset in childhood (age 2 or more up to 18 or less) - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Adalimumab (Humira® / Biosimilar) ICB Weekly use for treatment of psoriasis in adults Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE TA146 does not cover weekly use RED Adalimumab (biosimilar) (Imraldi® / Amjevita®) ICB Peripheral spondyloarthritis - following use of 3 DMARDs, as per local pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Adalimumab (biosimilar) various ICB weekly use for dose escalations in NICE-approved rheumatology indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Adefovir Hepsera ® NHSE Hepatitis B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG165 - Oct 17 Double Red ADHD drugs - various (Various) ICB First-line use in children and adolescents with ADHD - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 Double Red ADHD drugs - various (Various) ICB Use in pre-school children - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Afamelanotide Scenesse® NHSE erythropoietic protoporphyria Not commissioned. No NHS prescribing in primary or secondary care HST27 – July 2023 RED Afatinib ▼ (Giotrif® ▼) NHSE Treatment of epidermal growth factor X deficiency receptor mutation-positive locally advanced or metastatic non- small-cell lung cancer - as per NICE TA 310 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA310 - April 2014 BLACK Afatinib ▼ (Giotrif® ▼) NHSE Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy - as per NICE TA 444 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA444 - May 17 RED Aflibercept (Eylea®) ICB Treatment of Wet Age-related Macular Degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 RED Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 RED Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) in new patients Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 RED Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema secondary to central retinal vein occlusion (CRVO) - as per NICE TA 305 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA305 - Feb 14 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Aflibercept (Zaltrap®) NHSE Treatment of metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (along with irinotecan and fluorouracil-based therapy) - as per NICE TA 307 - NICE Do Not Do Not commissioned. No NHS prescribing in primary or secondary care TA307 - Mar 14 RED Aflibercept (Eylea®) ICB Treatment of visual impairment caused by diabetic macular oedema (DMO) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA346 - Jul 15 RED Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema after branch retinal vein occlusion - as per NICE TA 409 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA409 - Sep 16 RED Aflibercept (Eylea®) ICB Treatment of visual impairment due to myopic choroidal neovascularisation in adults - as per NICE TA 486 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA486 - Nov 17 RED Aflibercept (Eylea®) ICB Treatment of Diabetic Macular Oedema (DMO) as part of a treat and extend regimen in line with the locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Aflibercept (Eylea®) ICB Treatment of Wet Age-related Macular Degeneration (AMD) as part of a treat and extend regimen in line with the locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications RED Aflibercept (switched to Ranibizumab (Lucentis®) (Eylea®) ICB Switching between products in the treatment of Wet Age-related Macular Degeneration (AMD) in previously treated patients who have not responded adequately to, or who have intolerance to aflibercept (Eylea®) - as per locally commissioned pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor NG82 - Jan 18 RED Agalsidase alfa and beta (FEIBAReplagal® (alpha) / Fabrazyme® (beta)) NHSE Specialist indications Fabry disease (α-galactosidase A deficiency) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine Agomelatine (FampyraValdoxan®) NHSE Improvement of walking ICB 4th line use in adults with Multiple Sclerosis with walking disability depression where other treatments have failed or not been tolerated (EDSS 4-7terminated appraisal) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab VabysmoTA231 - Sep 11 RED Albumin bound paclitaxel Abraxane ® ICB diabetic macular oedema NHSE with gemcitabine for untreated metastatic pancreatic cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat TA476 - Sep 17 RED Albutrenpenon acog alfa (Adenuric®Idelvion) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol NHSE Haemophilia B - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care NHS England policy SSC1652 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. DM Albutropin NHSE Adult onset growth hormone deficiency . Discontinued Medicines NICE has not issued any guidance. RED Aldesleukin (Proleukin) NHSE Cancer - metastatic renal cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alectinib (Alecensa®) NHSE Untreated ALK-positive advanced non-small-cell lung cancer - as per NICE TA 536 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA536 - Aug 18 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Alectinib ▼ (Alecensa® ▼) NHSE Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - as per NICE TA 438 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA438 - Mar 17 RED Alemtuzumab (Lemtrada®) NHSE Chronic lymphocytic leukaemia (CLL) - as per NHS England policy 2013 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alemtuzumab (Lemtrada®) NHSE Pre-transplant immunosuppression Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alemtuzumab (MabCampat h®) NHSE Behcet's syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alemtuzumab ▼ (Lemtrada® ▼) NHSE Treatment of adults with relapsing- remitting multiple sclerosis (RRMS) - as per NICE TA 312 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA312 – May 2014, updated May 2024 Double Red Ferric maltol Alendronate / Vitamin D3 combination (Feraccru®) (Feraccru®Fosavance® ) ICB Treatment of iron-post menopausal osteoporosis in women at risk of vitamin D deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol GREEN Alendronic acid (Feraccrusodium alendronate) (Generics available) ICB Secondary prevention of osteoporotic fragility fractures in postmenopausal women - as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA161 - Oct 08 GREEN Alendronic acid (sodium alendronate) (Generic available) ICB Primary prevention of osteoporotic fragility fractures in postmenopausal women as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA464 - Aug 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Alfacalcidol (AlfaD®, One- Alpha®) ICB Preparation for hyperparathyroidectomy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. RED Alglucosidase alfa (FeraccruMyozyme®) NHSE Pompe disease (a lysosomal storage disorder caused by deficiency of acid alpha- glucosidase) - as per NHS England Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Alimemazine (Trimeprazine) (Generics) ICB Sedative in children / general antihistamine Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. RED Alipogene tiparvovec (Glybera®) NHSE (Gene therapy treatment for ) Lipoprotein lipase deficiency - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alirocumab ▼ (Praluent® ▼) ICB Treating primary hypercholesterolaemia and mixed dyslipidaemia - as per NICE TA 393 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA393 - Jun 16 BLACK Aliskiren ▼ (Rasilez® ▼) ICB Treatment of essential hypertension - as per NICE CG 127 Not commissioned. No NHS prescribing in primary or secondary care CG127 - Sep 11 Double Red Alisporivir ((aka Debio 025 / DEB025 / UNIL-025)) NHSE Viral Hepatitis C - as per NHSE policy Not recommended for routine use NICE has not issued any guidance. RED Alitretinoin (Toctino®) ICB Treatment of ironsevere chronic hand eczema - as per NICE TA 177 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA177 - Aug 09 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Alpelisib Piqray® NHSE with fulvestrant for treating hormone-receptor positive, HER2- negative, PIK3CA-positive advanced breast cancer (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA652 – October 2020 RED Alpelisib Piqray® NHSE with fulvestrant for treating hormone receptor-positive, HER2- negative, PIK3CA-mutated advanced breast cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA816 – August 2022 Double Red Alpha blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 . Not recommended for routine use CG101 - Jul 10 RED Alpha- mannosidase - recombinant human (Lamazym®) NHSE Alpha Mannosidase deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R Alprostadil cream (ToviazVitaros®) ICB Increased urinary frequency and/or urgency and/or urgency incontinenceErectile dysfunction (as per SLS conditions only) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 NICE has not issued any guidance. RED Alteplase (Actilyse®) ICB Treatment of acute ischaemic stroke - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue as per NICE TA 264 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried TA264 - Sep 12 Double Red Amantadine Hydrochloride (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (DificlirLysovir®) ICB Treatment and prophylaxis of mild to moderate C. difficile infection influenza Not recommended for routine use TA168 - Feb 09 RED Ambrisentan (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib (Volibris® ▼) NHSE Paediatric indications (where adult TA available) Pulmonary Arterial Hypertension - specialist centres centre only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib JyselecaRED Amifampridine (phosphate) ▼ (Firdapse® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration Treatment of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy myasthenias - Xxxxxxx-Xxxxx syndrome - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Amikacin - liposomal for inhalation (Arikace®) NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidanceGram-negative bacterial infection in Cystic Fibrosis . BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12NICE has not issued any guidance.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Double Red Clomethiazole (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraHeminevrin®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4PHE Community-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol based assisted alcohol withdrawal - as per NICE TA 164 CG 115 - Do Not Do Not recommended for routine use CG115 - Feb 11 GREEN Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Prevention of atherosclerotic events Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 TA210 - Dec 08 10 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted Clopidogrel (Plavix®, generics approved for use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®- Sept 2009) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl IProphylaxis pre-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care elective PCI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol Clopidogrel (FeraccruPlavix®) (Feraccru®, generics approved for use - Sept 2009) ICB Treatment Primary prevention of iron-deficiency anaemia CVD in adults (see separate Red entry regarding use in IBD) T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol NG17 - May 17 Double Red Clopidogrel (FeraccruPlavix®) (Feraccru®, generics approved for use - Sept 2009) ICB Treatment Primary prevention of iron-deficiency anaemia CVD in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital T1 or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia T2 Diabetes - as per BCSH guidelines Restricted NG17 and NG 28 Do Not Do's Not recommended for routine use – Prescribing to remain NG28 - May 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Clopidogrel (with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 low dose aspirin) (FGF1) gene therapy () NHSE All indications Restricted Plavix®, generics approved for use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®- Sept 2009) ICB Treatment of mild to moderate C. difficile infection Acute Coronary Syndrome without ST- segment elevation (CDINSTEMI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy (with aspirin) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script. TA80 - Jul 04 ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB Post elective percutaneous coronary intervention (PCI) - bare metal stent (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in-patient stay. NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication ADVICE Clopidogrel (assume with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB ST-elevation myocardial infarction (STEMI) (Not a licensed unless stated) Instructions indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for Prescriber an initial period of in patient stay; max one month. NICE Guidance has not issued any guidance. Hospital Filgotinib JyselecaClozapine (Clozaril®, Denzapine®, Zaponex®) ICB Moderate to severe rheumatoid arthritis Schizophrenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 CG82 - Mar 09 Hospital Filgotinib Cobicistat ▼ () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib JyselecaTybost® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction Use as a booster in the duration treatment of neutropenia HIV positive adults and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy adolescents - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod BLACK Cobimetinib ▼ (Gilenyain combination with vemurafenib) (Cotellic® ▼) NHSE Highly active relapsing remitting multiple sclerosis Unresectable or metastatic BRAF V600 mutation-positive melanoma - as per NICE TA 254 414 Not commissioned. No NHS prescribing in primary or secondary care TA414 - Oct 16 Hospital Co-careldopa intestinal gel (Duodopa® ▼) NHSE Severe Xxxxxxxxx'x disease inadequately controlled by other preparations - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 NICE has not issued any guidance. Hospital Cochlear implants (Various) NHSE For children and adults with severe to profound deafness - Apr 12specialist commissioned use only as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA566 - Mar 19 Double Red Codeine linctus generic ICB Cough suppressant Not recommended for routine use NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Co-enzyme Q10 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 17 BLACK Co-enzyme Q11 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 GREEN Colecalciferol (Vitamin D) (Licensed Vitamin D products) ICB Treatment of vitamin D deficiency in adults and children - as per local policies Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. BLACK Colecalciferol (Vitamin D) (Various) ICB To increase adherence to statin treatment - as per NICE CG 181 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 14 ADVICE Colesevelam HCl (Cholestagel®) ICB Third-line option for (unlicensed) use in bile salt malabsorption causing diarrhoea (for patients under the NNUH only) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 8 weeks (for new patients). NICE has not issued any guidance. Double Red Colesevelam HCl ▼ (Cholestagel® ▼) ICB Hypercholesterolaemia - as per NICE CG 181 Do Not Do Not recommended for routine use CG181 - Jul 14 Double Red Colesevelam hydrochloride (Cholestagel®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do Not recommended for routine use CG181 - Jul 14 Hospital Colestilan () NHSE Management of hyperphosphataemia in adults on renal dialysis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Colestipol hydrochloride (Colestid®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Double Red Colestyramine (Questran®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Colistimethate sodium (nebulised) (Colomycin®, Promixin®) NHSE Pseudomonas lung infection in Cystic Fibrosis (new patients from 1st April 2013) - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 AMB Colistimethate sodium (Colomycin®, Promixin®) ICB Ps. aeurginosa infection in non-Cystic Fibrosis bronchiectasis Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. (Nebulised) Hospital Colistimethate sodium Dry Powder Inhaler (Colobreathe® Dry Powder Inhaler) NHSE Pseudomonas lung infection in cystic fibrosis - as per NICE TA 276 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 DM Collagenase clostridium histolyticum (Xiapex®) ICB Dupuytren's contracture with a palpable cord in adults - as per NICE TA 459 Discontinued Medicines TA459 - Jul 17
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) Arimoclomol NHSE Hereditary factor X deficiency Xxxxxxx Pick disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Aripiprazole (Abilify®) ICB Moderate to severe manic episodes in adolescents with bipolar I disorder - as per NICE TA 292 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA292 - Jul 13 ADVICE Aripiprazole (Abilify®) ICB Schizophrenia and bipolar mood disorder - as per NICE CG 82 and TA 213 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG82 - Mar 09 BLACK Armour Thyroid / any unlicensed thyroid products (Armour Thyroid) ICB Any indication Not commissioned. No NHS prescribing in primary or secondary care RMOC guidance - June 2019 ADVICE Aromatase inhibitors (Various) (Various) ICB Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in post menopausal women - as per local protocol Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 Hospital Arsenic trioxide (Trisenox®) NHSE Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR- alpha gene) in adults - as per NICE TA 526 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA526 - Jun 18 GREEN Artificial saliva or salivary stimulants (Xerotin Oral spray or other cost- effective product) ICB Xerostomia from any cause where simple measures alone have been ineffective Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII Asciminib Scemblix® NHSE Specialist indications chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA813 – August 2022 Hospital Asfotase alfa Strensiq® NHSE paediatric-onset hypophosphatasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST23 – March 2023 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Double Red Asunaprevir (with Daclatasvir) () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. Hospital Atacicept () NHSE Systemic Lupus Erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Ataluren ▼ (FEIBATranslarna® ▼) NHSE Specialist indications Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged ≥5 years who can walk - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine HST22 - Feb 2023 Hospital Atazanavir (FampyraReyataz®) NHSE Improvement of walking HIV infection in adults combination with Multiple Sclerosis with walking disability (EDSS 4-7) other antiretroviral drugs - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue BHIVA Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried Atazanavir and Cobicistat (Human) (Evotaz®) NHSE Treatment of haemorrhage HIV infection in congenital hypofibrinogenaemia or afibrinogenaemia combination with other antiretroviral drugs - as per BCSH BHIVA guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 Atezolizumab (FGF1) gene therapy (Tecentriq®) NHSE All indications Locally advanced or metastatic non- small-cell lung cancer after chemotherapy - as per NICE TA 520 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation TA520 - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12May 18
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Factor X Heparin - Low Molecular Weight (CoagadexLMWH) NHSE Hereditary factor X deficiency (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Factor XIII HIV vaccine (HIV vaccine) NHSE Specialist indications HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor HIV/AIDS treatments (FEIBAVarious) NHSE Specialist indications HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 TA965 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 March 2024 Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays Hospital Human heterologous liver cells (Effentora®, Actiq®, Instanyl®, PecFentHHLivC) (Heparesc®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried Human Normal Immunoglobulin (HumanAragam®) (Aragam®) NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia As per National Demand Management Plan - as per BCSH guidelines NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 Human Normal Immunoglobulin (FGF1Flebogamma®) gene therapy (Flebogamma® ) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as As per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE Xxxxx Syndrome As per National Demand Management Plan - specialist centres only NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim Human normal immunoglobulin (Various ▼Gammanorm®) (Gammanorm® ) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy As per National Demand Management Plan - as per NHS England NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) As per National Demand Management Plan - NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - Apr 12NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Intratect®) (Intratect®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (IVIg) (Privigen®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Botulinum Toxin Type A (CoagadexDysport®) ICB Muscle spasticity in neuromuscular conditions - cerebral palsy - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Botulinum Toxin Type A (Botox®, Dysport®) ICB Treatment of focal spasticity in Multiple Sclerosis or following stroke or brain injury - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Botulinum Toxin Type A and B (Botox®) NHSE Hereditary factor X deficiency Intravesical use in spinal cord injury Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Botulinum Toxin Type A and B (Botox®) NHSE Focal spasticity in children Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Brentuximab vedotin (Adcetris®) NHSE CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease - as per NICE TA 524 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA524 - Jun 18 Hospital Brentuximab vedotin (Adcetris®) NHSE Treating CD30-positive cutaneous T- cell lymphoma (CTCL) after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome - as per NICE TA 577 (NHSE comm Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA577 - Apr 19 BLACK Brentuximab vedotin (Adcetris®) NHSE Untreated advanced Hodgkin lymphoma (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA594 - Aug 19 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Brentuximab vedotin (Adcetris®) NHSE in combination for untreated systemic anaplastic large cell lymphoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA641 – August 2020 Hospital Brentuximab vedotin ▼ (Adcetris® ▼) NHSE CD30-positive Hodgkin lymphoma - as per NICE TA 446 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA446 - Jun 17 Hospital Brentuximab vedotin ▼ (Adcetris® ▼) NHSE For treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - as per NICE TA 478 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA478 - Oct 17 Hospital Brexucabtagene autoleucel Tecartus® NHSE relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA893 – June 2023 Hospital Brigatinib (Alunbrig®) NHSE For treating ALK-positive advanced non-small-cell lung cancer in adults, after crizotinib - as per NICE TA 571 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA571 - Mar 19 Hospital Brigatinib Alunbrig® NHSE ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA670 – January 2021 Hospital Brimapitide NHSE Acute sensorineural hearing loss Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Brimonidine tartrate gel (Mirvaso®) ICB Treatment of facial erythema (rosacea) Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Brincidofovir ((CMX001)) NHSE CMV infection Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance ADVICE Brivaracetam Briviact ICB epilepsy as alternative to levetiracetam Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Factor XIII NHSE Specialist indications Brodalumab (Kyntheum®) ICB Moderate to severe plaque psoriasis - as per NICE TA 511 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA511 - Mar 18 Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab VabysmoBrolucizumab Beovu® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet Wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 TA672 – June February 2021 BLUE Brolucizumab Beovu® ICB diabetic macular oedema NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA820 – August 2022 GREEN Febuxostat BLACK Bromocriptine (Adenuric®) ICB Management of chronic hyperuricaemia Pharmacological neuroprotective therapy in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" Xxxxxxxxx'x disease (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 BLACK Bromocriptine mesilate (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFentParlodel®) ICB First-line use in Xxxxxxxxx'x disease - as per NICE NG 17 Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 ADVICE Budenofalk (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (AbstralBudenofalk®) ICB 3rd line option for (Acute) breakthrough pain Crohn's disease in cancer as part of an agreed pathway of adults Formulary - Specialist advice required from primary or secondary care Restricted use – Prescribing clinician with relevant expertise prior to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care initiation NICE has not issued any guidance. ADVICE Fidaxomicin Budenofalk (DificlirBudesonide 3mg caps & 9mg granules) (Budenofalk®) ICB Treatment of mild to moderate C. difficile infection (CDI) Collagenous colitis in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®Budesonide (oral viscous slurry) Pulmicort respules ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing eosinophilic oesophagitis in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only adults and paediatrics Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidanceguidance BLACK Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults - treatment for maintenance of remission Not commissioned. No NHS prescribing in primary or secondary care TA708 – June 2021 ADVICE Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (GP may issue a SINGLE follow-up treatment (NOT for repeat) only if deemed necessary following assessment of response to initial treatment by given the hospital) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. TA708 – June 2021 Hospital Filgotinib Jyseleca® Budesonide orodispersible tablets (Jorveza®) ICB moderately to severely active ulcerative colitis Eosinophilic oesophagitis in adults (first treatment with follow-up assessment of effectiveness by the hospital) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 TA708 – June 2022 2021 Hospital Filgrastim () Bulevirtide Hepcludex® NHSE Xxxxx Syndrome - specialist centres only chronic hepatitis D Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA896 – June 2023 GREEN Buprenorphine (sublingual & oral lyophilisate) (Subutex® - generics available / Espranor®) NCC Opioid dependence (for use by prescribers with competence in treating opioid dependence) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Filgrastim ADVICE Buprenorphine (Various ▼transdermal) NHSE Reduction in the duration (Butec®, Transtec® patches) ICB Patients with renal impairment (eGFR 15-30, CKD 4) who have an accumulation of neutropenia opiates and the incidence of febrile neutropenia in patients treated a resulting potential for toxicity Formulary - Specialist advice required from primary or secondary care clinician with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing relevant expertise prior to remain with the hospital or specialist service. No prescribing in primary care initiation NICE has not issued any guidance. Double Red Filibuvir Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) NHSE Viral Hepatitis (B&CInstructions for Prescriber NICE Guidance BLUE Buprenorphine Long- Acting Injection Buvidal®) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes opioid substitution treatment NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 RMOC - April 2021 GREEN Bupropion (Zyban®) NCC Adjunct to smoking cessation Formulary - Drugs that can be initiated by Prescriber in Primary Care NG92 - Mar 18 Hospital Fingolimod ▼ Burosumab (Gilenya® ▼Crysvita®) NHSE Highly active relapsing remitting multiple sclerosis X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in young people with growing bones - as per NICE TA 254 HST 8 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 HST8 - Oct 18 Double Red Buspirone (Generics are available) ICB Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do Not recommended for routine use CG90 - Oct 09 Hospital Busulfan (Myleran®) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Butyrophenones (benperidol and haloperidol) (Various) ICB NICE Do Not Do - Use in Xxxxxxxxx'x disease - as per NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Hospital C1 Esterase Inhibitors NHSE Hereditary angioedema treatment and prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Cabazitaxel (Jevtana®) NHSE Hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen - as per NICE TA 255 Not commissioned. No NHS prescribing in primary or secondary care TA255 - May 12 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Cabazitaxel (Jevtana®) NHSE Metastatic hormone relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy - as per NICE TA 391 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA391 - Aug 16 BLACK Cabergoline (Cabaser®) ICB First-line use in Xxxxxxxxx'x disease - as per NICE NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Hospital Cabotegravir Vocabria® NHSE HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Cabotegravir Vocabria® NHSE with rilpivirine for treating HIV-1 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA757 – January 2022 Hospital Cabozantinib (Cometriq®) NHSE For treating medullary thyroid cancer - as per NICE TA 516 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA516 - Mar 18 Hospital Cabozantinib (Cabometyx®) NHSE Untreated advanced renal cell carcinoma in adults under defined circumstances - as per NICE TA 542 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA542 - Oct 18 Hospital Cabozantinib Cabometyx® NHSE previously treated advanced hepatocellular carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA849 – December 2022 BLACK Cabozantinib Cabometyx® NHSE previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine Not commissioned. No NHS prescribing in primary or secondary care TA928 – November 2023 Hospital Cabozantinib Cabometyx® NHSE with nivolumab for untreated advanced renal cell carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA964 – April 2024 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Cabozantinib ▼ (Cabometyx® ▼) NHSE Previously treated advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)- targeted therapy - as per NICE TA 463 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA463 - Aug 17 Hospital Calcifidiol NHSE Inborn errors in primary bile acid synthesis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Calcium and Ergocalciferol combi tablets (Generic tablets) ICB Prevention of osteoporosis-related fractures and falls Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Double Red Calcium channel blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 - NICE Do Not Do Not recommended for routine use CG101 - Jul 10 ADVICE Canagliflozin ▼ (Invokana® ▼) ICB In combination therapy for treating type 2 diabetes - as per NICE TA 315 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA315 - Jun 14 ADVICE Canagliflozin ▼ (Invokana® ▼) ICB As a 4th monotherapy option for treating type 2 diabetes - as per NICE TA 390 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA390 - May 16 BLACK Canakinumab (Ilaris®) ICB Treatment of gouty arthritis attacks and reducing the frequency of subsequent attacks - as per NICE TA 281 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA281 - Apr 1213 BLACK Canakinumab (Ilaris®) NHSE Treatment of systemic juvenile idiopathic arthritis - - as per NHS England policy (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA302 - Nov 13 BLACK Cangrelor ▼ (Kengrexal® ▼) ICB Treatment for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti platelet therapy - as per NICE TA 351 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA351 - Jul 15
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Bevacizumab (CoagadexAvastin®) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications ICB Radiation retinopathy macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Bexarotene (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraTargretin®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin Double Red Bezafibrate (DificlirBezalip; Fibrazate) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" Not recommended for routine use CG181 - Jul 14 BLACK Bezlotoxumab (Zinplava®) ICB Treatment Prevention of mild to moderate C. recurrent clostridium difficile infection (CDIterminated appraisal) Not commissioned. No NHS prescribing in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician TA601 - Sep 19 Hospital Bictecravir (in combination with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless statedemtricitabine and tenofivir alafenamide) Instructions for Prescriber NICE Guidance Hospital Filgotinib JyselecaBiktarvy ®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim Bimagrumab ((BYM338)) NHSE Xxxxx Syndrome - specialist centres only Inclusion body myositis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim Bimekizumab Bimzelx® ICB active psoriatic arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA916 – October 2023 Traffic Light Classification Drug Name Brand Name Commissione r Indication (Various ▼assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Bimekizumab Bimzelx® ICB axial spondyloarthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA918 – October 2023 Hospital Bimekizumab Bimzelx® ICB moderate to severe plaque psoriasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA723 – September 2021 Hospital Binimetinib (Mektovi®) NHSE Reduction (with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy adults - as per NICE TA 562 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA562 - Feb 19 BLACK Bioidentical HRT (Bioidentical hormone replacement therapy) ICB Menopausal symptoms Not commissioned. No NHS England policy prescribing in primary or secondary care NG23 - Nov 13 Hospital Biotin (vitamin H) (Qizenday®, Cerenday®, MD1003) NHSE various Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () Hospital Birch bark extract n/a NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 epidermolysis bullosa Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 HST28 – September 2023 Hospital Bivalirudin (Angiox®) ICB Treatment of ST-segment-elevation myocardial infarction - Apr 12as per NICE TA 230 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA230 - Jul 11 Hospital Blinatumomab (Blincyto®) NHSE Acute lymphoblastic leukaemia in remission with minimal residual disease activity Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA589 - Jul 19 BLACK Blinatumomab N/A NHSE previously treated Philadelphia- chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA686 – March 2021
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) Arimoclomol NHSE Hereditary factor X deficiency Xxxxxxx Pick disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Aripiprazole (Abilify®) ICB Moderate to severe manic episodes in adolescents with bipolar I disorder - as per NICE TA 292 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA292 - Jul 13 ADVICE Aripiprazole (Abilify®) ICB Schizophrenia and bipolar mood disorder - as per NICE CG 82 and TA 213 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG82 - Mar 09 BLACK Armour Thyroid / any unlicensed thyroid products (Armour Thyroid) ICB Any indication Not commissioned. No NHS prescribing in primary or secondary care RMOC guidance - June 2019 ADVICE Aromatase inhibitors (Various) (Various) ICB Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in post menopausal women - as per local protocol Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 Hospital Arsenic trioxide (Trisenox®) NHSE Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR- alpha gene) in adults - as per NICE TA 526 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA526 - Jun 18 GREEN Artificial saliva or salivary stimulants (Xerotin Oral spray or other cost- effective product) ICB Xerostomia from any cause where simple measures alone have been ineffective Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII Asciminib Scemblix® NHSE Specialist indications chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA813 – August 2022 Hospital Asfotase alfa Strensiq® NHSE paediatric-onset hypophosphatasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST23 – March 2023 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Double Red Asunaprevir (with Daclatasvir) () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. Hospital Atacicept () NHSE Systemic Lupus Erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Ataluren ▼ (FEIBATranslarna® ▼) NHSE Specialist indications Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged ≥5 years who can walk - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine HST22 - Feb 2023 Hospital Atazanavir (FampyraReyataz®) NHSE Improvement of walking HIV infection in adults combination with Multiple Sclerosis with walking disability (EDSS 4-7) other antiretroviral drugs - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue BHIVA Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried Atazanavir and Cobicistat (Human) (Evotaz®) NHSE Treatment of haemorrhage HIV infection in congenital hypofibrinogenaemia or afibrinogenaemia combination with other antiretroviral drugs - as per BCSH BHIVA guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 Atezolizumab (FGF1) gene therapy (Tecentriq®) NHSE All indications Locally advanced or metastatic non- small-cell lung cancer after chemotherapy - as per NICE TA 520 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation TA520 - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12May 18
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidanceTA47 - Sep 02 Hospital Eptinezumab VYEPTI® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA871 – March 2023 Hospital Factor X Eptotermin alfa (Coagadex) NHSE Hereditary factor X deficiency Complex spinal surgery Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Erectile dysfunction drugs (Various) ICB Erectile dysfunction - limited categories of patients under SLS for certain drugs Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Factor XIII NHSE Specialist indications Erectile dysfunction drugs (Various) ICB Severe distress from erectile dysfunction seeking treatment on the NHS Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab VabysmoBLUE Erenumab Aimovig® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes Preventing migraine NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- TA682 – March 2023 2021 Hospital Fingolimod ▼ Eribulin (Gilenya® ▼Halaven®) NHSE Highly active relapsing remitting multiple sclerosis Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens only when it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine) - as per NICE TA 254 423 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 TA423 - Apr 12Dec 16 Hospital Eribulin (Halaven®) NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 423 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 BLACK Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 1 chemotherapy regimen - as per NICE TA 515 Not commissioned. No NHS prescribing in primary or secondary care TA515 - Mar 18 BLACK Erlotinib (Tarceva®) NHSE Monotherapy for maintenance treatment of non-small-cell lung cancer - as per NICE TA 227 and NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA227 - Jun 11 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Erlotinib (Tarceva®) NHSE First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer - as per NICE TA 258 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA258 - Jun 12 BLACK Erlotinib (Tarceva®) NHSE Treatment of non-small-cell lung cancer (NSCLC) as per NICE TA 374 - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 BLACK Erlotinib (Tarceva®) NHSE Treating locally advanced or metastatic NSCLC that doesn’t test positive for the EGFR TK mutation (as per NICE TA 374) (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 ADVICE Ertugliflozin (Steglatro®) ICB As monotherapy or with metformin for treating type 2 diabetes - as per NICE TA 572 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA572 - Mar 19 GREEN Ertugliflozin (Steglatro®) ICB With metformin and a depeptidyl peptidase-4 inhibitor for Type 2 diabetes Formulary - Drugs that can be initiated by Prescriber in Primary Care TA583 - Jun 19 Hospital Erythropoietin (epoetin / darbepoetin) (Various) ICB Treatment of anaemia in people with cancer having chemotherapy - as per NICE TA 323 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA323 - Nov 14 Hospital Erythropoietin / Epoetin (Eprex) ICB Treatment of transfusion-dependent anaemia in myelodysplasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Erythropoietin / Epoetin (Eprex®, NeoRecormon® and others) NHSE Dialysis-induced anaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG114 - Nov 11 Double Red Erythropoietin / Epoetin (Eprex®, NeoRecormon® and others) ICB Anaemia in renal failure pre-dialysis. Not recommended for routine use NG8 - Jun 15 BLACK Esketamine Spravato® ICB nasal spray for treatment-resistant depression Not commissioned. No NHS prescribing in primary or secondary care TA854 – December 2022
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X RED Botulinum Toxin Type A (CoagadexDysport®) NHSE Hereditary factor X deficiency ICB Muscle spasticity in neuromuscular conditions - cerebral palsy - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Botulinum Toxin Type A (Botox®, Dysport®) ICB Treatment of focal spasticity in Multiple Sclerosis or following stroke or brain injury - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII RED Botulinum Toxin Type A and B (Botox®) NHSE Specialist indications Intravesical use in spinal cord injury Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor RED Botulinum Toxin Type A and B (FEIBABotox®) NHSE Specialist indications Focal spasticity in children Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Brentuximab vedotin (Adcetris®) NHSE CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease - as per NICE TA 524 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA524 - Jun 18 RED Brentuximab vedotin (Adcetris®) NHSE Treating CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome - as per NICE TA 577 (NHSE comm Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA577 - Apr 19 BLACK Brentuximab vedotin (Adcetris®) NHSE Untreated advanced Hodgkin lymphoma (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA594 - Aug 19 RED Brentuximab vedotin (Adcetris®) NHSE in combination for untreated systemic anaplastic large cell lymphoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA641 – August 2020 RED Brentuximab vedotin ▼ (Adcetris® ▼) NHSE CD30-positive Hodgkin lymphoma - as per NICE TA 446 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA446 - Jun 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Brentuximab vedotin ▼ (Adcetris® ▼) NHSE For treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - as per NICE TA 478 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA478 - Oct 17 RED Brexucabtage ne autoleucel Tecartus® NHSE relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA893 – June 2023 RED Brigatinib (Alunbrig®) NHSE For treating ALK-positive advanced non-small-cell lung cancer in adults, after crizotinib - as per NICE TA 571 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA571 - Mar 19 RED Brigatinib Alunbrig® NHSE ALK-positive advanced non-small- cell lung cancer that has not been previously treated with an ALK inhibitor Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA670 – January 2021 RED Brimapitide NHSE Acute sensorineural hearing loss Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine Brimonidine tartrate gel (FampyraMirvaso®) NHSE Improvement ICB Treatment of walking in adults with Multiple Sclerosis with walking disability facial erythema (EDSS 4-7rosacea) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat RED Brincidofovir (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indicationCMX001). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications CMV infection Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) Brivaracetam Briviact ICB Treatment of mild epilepsy as alternative to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy levetiracetam Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib JyselecaRED Brodalumab (Kyntheum®) ICB Moderate to severe rheumatoid arthritis plaque psoriasis - as per NICE TA 511 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) TA511 - specialist centres only Mar 18 RED Brolucizumab Beovu® ICB Wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib JyselecaTA672 – February 2021 BLUE Brolucizumab Beovu® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes diabetic macular oedema NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ TA820 – August 2022 BLACK Bromocriptine (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis ICB Pharmacological neuroprotective therapy in Xxxxxxxxx'x disease (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 BLACK Bromocriptine mesilate (Parlodel®) ICB First-line use in Xxxxxxxxx'x disease - as per NICE TA 254 NG 17 Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 ADVICE Budenofalk (Budenofalk® ) ICB Crohn's disease in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. ADVICE Budenofalk (Budesonide 3mg caps & 9mg granules) (Budenofalk® ) ICB Collagenous colitis in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Budesonide (oral viscous slurry) Pulmicort respules ICB eosinophilic oesophagitis in adults and paediatrics Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 NICE has not issued any guidance BLACK Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults - treatment for maintenance of remission Not commissioned. No NHS prescribing in primary or secondary care TA708 – June 2021 ADVICE Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (GP may issue a SINGLE follow-up treatment (NOT for repeat) only if deemed necessary following assessment of response to initial treatment by given the hospital) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. TA708 – June 2021 RED Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (first treatment with follow-up assessment of effectiveness by the hospital) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA708 – June 2021 RED Bulevirtide Hepcludex® NHSE chronic hepatitis D Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA896 – June 2023 GREEN Buprenorphine (sublingual & oral lyophilisate) (Subutex® - generics available / Espranor®) NCC Opioid dependence (for use by prescribers with competence in treating opioid dependence) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. ADVICE Buprenorphine (transdermal) (Butec®, Transtec® patches) ICB Patients with renal impairment (eGFR 15-30, CKD 4) who have an accumulation of opiates and a resulting potential for toxicity Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLUE Buprenorphine Long-Acting Injection Buvidal®) ICB opioid substitution treatment NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required RMOC - April 2021 GREEN Bupropion (Zyban®) NCC Adjunct to smoking cessation Formulary - Drugs that can be initiated by Prescriber in Primary Care NG92 - Mar 18 BLACK Bupropion (Zyban®) ICB ADHD and other mental health conditions Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. RED Burosumab Crysvita®) NHSE X-linked hypophosphataemia in adults Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA993 – August 2024 RED Burosumab (Crysvita®) NHSE X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in young people with growing bones - as per NICE HST 8 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST8 - Oct 18 updated Sept 2024 Double Red Buspirone (Generics are available) ICB Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do Not recommended for routine use CG90 - Oct 09 RED Busulfan (Myleran®) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Butyrophenon es (benperidol and haloperidol) (Various) ICB NICE Do Not Do - Use in Xxxxxxxxx'x disease - as per NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 RED C1 Esterase Inhibitors NHSE Hereditary angioedema treatment and prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Cabazitaxel (Jevtana®) NHSE Hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen - as per NICE TA 255 Not commissioned. No NHS prescribing in primary or secondary care TA255 - May 12 RED Cabazitaxel (Jevtana®) NHSE Metastatic hormone relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy - as per NICE TA 391 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA391 - Aug 16 BLACK Cabergoline (Cabaser®) ICB First-line use in Xxxxxxxxx'x disease - as per NICE NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 RED Cabotegravir Vocabria® NHSE HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Cabotegravir Vocabria® NHSE with rilpivirine for treating HIV-1 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA757 – January 2022 RED Cabozantinib (Cometriq®) NHSE For treating medullary thyroid cancer - as per NICE TA 516 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA516 - Mar 18 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Cabozantinib (Cabometyx ®) NHSE Untreated advanced renal cell carcinoma in adults under defined circumstances - as per NICE TA 542 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA542 - Oct 18 RED Cabozantinib Cabometyx® NHSE previously treated advanced hepatocellular carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA849 – December 2022 BLACK Cabozantinib Cabometyx® NHSE previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine Not commissioned. No NHS prescribing in primary or secondary care TA928 – November 20 RED Cabozantinib Cabometyx® NHSE with nivolumab for untreated advanced renal cell carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA964 – April 2024 RED Cabozantinib ▼ (Cabometyx ® ▼) NHSE Previously treated advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)-targeted therapy - as per NICE TA 463 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA463 - Aug 17 RED Calcifidiol NHSE Inborn errors in primary bile acid synthesis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Calcium and Ergocalciferol combi tablets (Generic tablets) ICB Prevention of osteoporosis-related fractures and falls Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Double Red Calcium channel blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 - NICE Do Not Do Not recommended for routine use CG101 - Jul 10 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Canagliflozin ▼ (Invokana® ▼) ICB In combination therapy for treating type 2 diabetes - as per NICE TA 315 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA315 - Jun 14 ADVICE Canagliflozin ▼ (Invokana® ▼) ICB As a 4th monotherapy option for treating type 2 diabetes - as per NICE TA 390 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA390 - May 16 BLACK Canakinumab (Ilaris®) ICB Treatment of gouty arthritis attacks and reducing the frequency of subsequent attacks - as per NICE TA 281 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA281 - Apr 1213 BLACK Canakinumab (Ilaris®) NHSE Treatment of systemic juvenile idiopathic arthritis - - as per NHS England policy (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA302 - Nov 13 BLACK Cangrelor ▼ (Kengrexal® ▼) ICB Treatment for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti platelet therapy - as per NICE TA 351 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA351 - Jul 15 RED Cannabidiol Epidyolex® NHSE seizures caused by tuberous sclerosis complex Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA873 – March 2023 RED Cannabidiol with clobazam (Epidyolex®) NHSE Seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA614 - Dec 19
Appears in 1 contract
Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidanceTA47 - Sep 02 RED Eptinezumab VYEPTI® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. Hospital Factor X No prescribing in primary care TA871 – March 2023 RED Eptotermin alfa (Coagadex) NHSE Hereditary factor X deficiency Complex spinal surgery Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications GREEN Erectile dysfunction drugs (Various) ICB Erectile dysfunction - limited categories of patients under SLS for certain drugs Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. RED Erectile dysfunction drugs (Various) ICB Severe distress from erectile dysfunction seeking treatment on the NHS Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab VabysmoBLUE Erenumab Aimovig® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes Preventing migraine NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- TA682 – March 2023 Hospital Fingolimod ▼ 2021 ADVICE Ergocalciferol / Vitamin D Injections ICB Vitamin D deficiency Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. RED Eribulin (Gilenya® ▼Halaven®) NHSE Highly active relapsing remitting multiple sclerosis Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens only when it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine) - as per NICE TA 254 423 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 TA423 - Apr 12Dec 16 RED Eribulin (Halaven®) NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 423 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 1 chemotherapy regimen - as per NICE TA 515 Not commissioned. No NHS prescribing in primary or secondary care TA515 - Mar 18 BLACK Erlotinib (Tarceva®) NHSE Monotherapy for maintenance treatment of non-small-cell lung cancer - as per NICE TA 227 and NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA227 - Jun 11 RED Erlotinib (Tarceva®) NHSE First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer - as per NICE TA 258 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA258 - Jun 12 BLACK Erlotinib (Tarceva®) NHSE Treatment of non-small-cell lung cancer (NSCLC) as per NICE TA 374 - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 BLACK Erlotinib (Tarceva®) NHSE Treating locally advanced or metastatic NSCLC that doesn’t test positive for the EGFR TK mutation (as per NICE TA 374) (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 ADVICE Ertugliflozin (Steglatro®) ICB As monotherapy or with metformin for treating type 2 diabetes - as per NICE TA 572 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA572 - Mar 19 GREEN Ertugliflozin (Steglatro®) ICB With metformin and a depeptidyl peptidase-4 inhibitor for Type 2 diabetes Formulary - Drugs that can be initiated by Prescriber in Primary Care TA583 - Jun 19 RED Erythropoietin (epoetin / darbepoetin) (Various) ICB Treatment of anaemia in people with cancer having chemotherapy - as per NICE TA 323 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA323 - Nov 14 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Erythropoietin / Epoetin (Eprex) ICB Treatment of transfusion- dependent anaemia in myelodysplasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Erythropoietin / Epoetin (Eprex®, NeoRecormo n® and others) NHSE Dialysis-induced anaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG114 - Nov 11 Double Red Erythropoietin / Epoetin (Eprex®, NeoRecormo n® and others) ICB Anaemia in renal failure pre- dialysis. Not recommended for routine use NG8 - Jun 15 BLACK Esketamine Spravato® ICB nasal spray for treatment-resistant depression Not commissioned. No NHS prescribing in primary or secondary care TA854 – December 2022 BLACK Esketamine Spravato® ICB major depressive disorder in adults at imminent risk of suicide (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA899 – June 2023 BLACK Eslicarbazepin e Zebinix® ICB Epilepsy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Eslicarbazepin e Zebinix® ICB Trigeminal neuralgia Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. ADVICE Esomeprazole (Generic) ICB Limited use where other PPI options have been ineffective; Xxxxxxx'x oesophagus Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Double Red Esomeprazole (Nexium®, Emozul®, Generic available) ICB First line PPI option for licensed indications - Not recommended for routine use NICE has not issued any guidance.
Appears in 1 contract
